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Summary 
Obesity is becoming one of the most widespread non-communicable diseases in the world. 
Associated with obesity are various metabolic disorders, such as sleep apnea, non-alcoholic 
fatty disease and arthritis, all contributing to a decreased quality of life and great expanses on 
the health services world wide.  
In all metabolic disorders identified, an increase in serum C-reactive protein (CRP) and low 
grade chronic inflammation is observed. This is thought to be one of the causes for the 
development of metabolic disorders, and involve macrophage infiltration of white adipose 
tissue (WAT), and the production of inflammatory markers such as Tumor necrosis factor- α 
(TNF- α), Interlukin-6 (IL-6), IL-1β, IL-8. When fat mass is reduced in obese subjects, the 
levels of these markers are reduced. Hence, low grade inflammation has been associated with 
pathological levels of WAT.   
In a pilot study we have investigated if WAT of obese patients were infiltrated by immune 
cells causing inflammation. Pre surgery adipose tissue from patients undergoing gastric 
bypass at Oslo University Hospital Aker (OUHA) were used to optimize a method for the 
isolation of immune cells of WAT in order to determine the identity of infiltrating cells by 
flow cytometry. Moreover, WAT from patients undergoing bariatric surgery at OUHA and 
Haukeland University Hospital (HUH) were also analyzed histological and by immune 
histochemistry. Together our results demonstrated that immune cell infiltration in general was 
low both in subcutaneous as well as omental WAT. Interestingly, immune cell infiltration 
appeared more pronounced one year post- compared to pre surgery. Infiltration was observed 
as low number of B and T cells as well as macrophage aggregates described as “crown-like 
structures” (CLS). CLS are structures surrounding necrotic adipocytes. Infiltrates were only 
observed post surgery whereas we did not observe this phenomenon in pre surgery WAT. Our 
findings were unexpected since CLS´ have only been documented prior to substantial weight 
loss. Our results propose that immune cells infiltration also takes place post surgery in WAT. 
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1 Introduction 
1.1 Overweight and obesity: a global perspective 
The attitudes towards overweight and obesity have changed throughout the history. 
Hippocrates (460 BC-ca 370 BC) early described obesity as a disease, whereas overweight 
and obesity represented wealth and prosperity in the 17th century. Social trends maintained 
the positive association towards overweight and obesity until the beginning of the 20th 
century, where the negative health risks associated to overweight and obesity were revealed 
[1, 2]. Research continues to show how overweight and obesity are strong contributors to the 
development of chronic diseases, such as type 2 diabetes mellitus (T2DM), hypertension 
(HT), cardiovascular diseases (CVD) and dyslipidemia, and increases the risk of some 
cancers. Overweight and obesity also negatively affect the quality of life and increase the 
economical expenses in terms of health costs and social services in our society and healthcare 
system [3-5]. In addition to findings from research, the general opinion on overweight and 
obesity is becoming similar to the one Hippocrates had; it is a disease. 
Developed countries have over the last decades experienced an increase in obesity among the 
populations about to reach epidemic measures, and recent observations indicate that 
developing countries are undergoing similar trend, mainly due to the rapid industrialization 
occurring [6]. During the last 10 years (1992-2002) the prevalence of the overweight and 
obese population in China, defined by the World Health Organization (WHO) standard 
(Overweight and obesity (kg/m
2): body mass index (BMI) ≥ 24 kg/m2), has increased from 
14.6- 21.8% (Wang, Mi et al. 2007), whereas 66.3 % of the American population is either 
overweight or obese (BMI > 25 kg/m
2
) [7]. Of this 66.3%, 35.1 % of the adults are considered 
obese, defined by a BMI above 30 kg/m
2
 [8]. And this development does not appear to slow 
down by any measures. 
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Table 1.1. The International Classification of adult normal weight, overweight and obesity according to 
BMI.  From Sheipe 2006, http://who.int [9, 10] 
 
 
Seeing as the trend is comparable all over the globe in respect to the sharp increase of adverse 
obesity related complications and diseases on population level and economical loss in terms 
of lost labor, higher rates of sick leaves, reduced life expectancy [5], there have never been 
greater incentives for developing treatments, projects, pharmaceutical products, surgical 
methods etc. in order to combat obesity. 
1.2 Obesity linked to low grade chronic 
inflammation 
1.2.1 Adipose tissue in obesity 
The adipose tissue is now recognized as the largest endocrine organ in the body, rather than 
just energy storage and thermal and mechanical insulation [11-13]. The adipose tissue 
consists of adipocytes; and the stromal and vascular cells (SV cells or non-fat cells), which 
include fibroblasts, mast cells, vascular endothelial cells, resident macrophages, leukocytes, 
and other inflammatory cells. The stromal vascular fraction (SVF) is recognized to be 
essential for adipose tissue inflammation [14-17].  
The adipose tissue secretes inflammatory factors, called adipokines, which are contributors to 
metabolic disease [18]  (Figure 1.1). It is thought that visceral adipose tissue of obese 
subjects has a higher metabolic activity than subcutaneous adipose tissue, with a greater 
production and secretion of inflammatory factors [19, 20]. 
Classification
BMI cut-off 
point (kg/m
2
)
Normal range 18.5 - 24.9
Overweight 25 - 29.9
Obesity 30 - 39.9
Obese class I 30 – 34.9
Obese class II 35 – 39.9
Morbid obesity 
(Obese class III)
40 – 49.9
Super obesity > 50
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1.2.2 Proinflammation 
A functioning immune system differentiates between foreign infectious agents and self, it this 
way it have the ability to successfully combat infectious agents. In normal situations this 
occurs without causing undue harm to the surrounding tissues, however if this control is lost, 
inflammation develops, and unless the immune response is turned 
off, the inflammation becomes chronic. Proinflammation or low 
grade chronic inflammations, which have been thought to be 
beneficial to the host, are also a sequel to a variety of infectious 
diseases. In fact proinflammation is a causal factor in the 
development of diabetes and atherosclerosis, which are hallmarks 
of metabolic syndrome (Figure 1.1) [20].  
Figure 1.1. Overview of the development of metabolic syndrome initiated by proinflammatory cytokines. 
From Cancello and Clement 2006 [20]. 
1.2.3 The adipokines and the inflammatory cytokines 
 
 
Figure 1.2. Adipokines and inflammatory cytokines specifically expressed and secreted by WAT. From 
Cancello and Clement 2006 [20]. 
Findings show that the amount of adipokines and leptin secreted from the adipose tissue is 
positively correlated to an increase in fat mass, adipocyte volume, BMI and with degree of 
insulin resistance, whereas the opposite apply for adiponectin [18, 19, 21].  
The majority of the adipokines are secreted from the non-fat cells (from the SVF) and 
elevated in obesity, and these include TNF- α, IL-8, IL-10, IL-6 and IL-1 β. Leptin is secreted 
Proinflammatory cytokines
Chronic inflammation
Insulin resistance syndrome
Hypertension, 
Hyperinsulinemia
Glucose intolerance, 
Dyslipedemia
Abdominal obesity
Metabolic Syndrome
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exclusively from adipocytes, whereas adiponectin is secreted from both the adipocytes and 
the non-fat cells [15]. Monocyte chemo attractant-1 (MCP-1), intracellular adhesion 
molecule-1 (ICAM-1), plasminogen activator inhibitor-1 (PAI-1) and free fatty acids (FFA) 
are examples of other adipokines secreted from the adipose tissue [15, 18, 21, 22]. 
TNF-α is a pro-inflammatory factor which is extensively produced by the adipose tissue in 
obesity. It causes insulin resistance as it prevents insulin receptor signaling [23]. An 
improvement in insulin sensitivity has been observed by the use of TNF- α in obese animals 
and decrease in TNF- α secretion has been observed after weight loss [20, 24]. The pro-
inflammatory IL-1β is thought to together with TNF- α up regulate the expression of IL-6 and 
IL-8. IL-6 is in turn positively correlated with C-reactive protein (CRP) [15, 25]. CRP is an 
acute-phase protein reflecting inflammatory processes which are found to be elevated in obese 
individuals when compared to non-obese individuals [12, 26].  Macrophages are the main 
target of MCP-1. MCP-1 recruit monocytes and has been found to be elevated in 
subcutaneous adipose tissue of obese women [27]. 
1.2.4 Obesity as an inflammation 
 
Figure 1.3. Chronic inflammation and adipocytes IR theoretically presented. From Xu, Barnes et al. 2003 
[28] 
Upon the gradual expansion of visceral adipose tissue when the body is in constant positive 
caloric balance, the mature adipocytes experience an enlargement, called hypertrophy. 
Whether preadipocytes undergo adipogenesis to become mature adipocytes in order to store 
the excess energy (hyperplasia) or the adipocytes expand (hypertrophy), is genetically 
determined. Research has shown that hyperplasia is less pathogenic and hypertrophy is 
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thought to result in adipocytes dysfunction, and one of the factors contributing to the increase 
in the inflammatory factors and the development of metabolic diseases [19].  
When tissues are expanding the need for blood supply emerges, including adipose tissue. 
However when angiogenesis is delayed, hypoxia occurs. Hypoxia is well known to induce 
macrophage recruitment and proinflammatory response [19, 20]. What it is specifically that 
initiate the immune response seen in obesity, whether it is the hypertrophy, the hypoxia or the 
elevated cytokine secretion, is unknown. But what is acknowledged is that the 
proinflammatory response is initiated and macrophages are activated, where the resident 
macrophages secrete cytokines that can impair insulin sensitivity locally in the adipocytes. 
This further stimulates the infiltration of peripheral monocytes and macrophages into the fat, 
which is thought to surround the adipocytes in a CLS. TNF-α secretion stimulates cytokine 
release (MCP-1, IL-1β, FFA) from preadipocytes, enhancing the macrophage infiltration. T 
lymphocytes appear in chronic inflammation and have been associated in obesity, thought to 
be activated by the adipokines [29-31].  This is amplifying cascade of events causes lipolysis 
as the insulin resistance (IR) is enhanced and in which eventually can result in systemic IR, 
development of T2DM, HT and the other metabolic disorders associated with obesity [19, 20, 
22, 27, 28, 32, 33]. 
With in mind that the visceral adipose tissue is regarded as more metabolic active than the 
subcutaneous adipose tissue, it is understandable that location of adipose tissue accumulation 
plays a role in terms of the co-morbidities associated to obesity. Excess central adiposity 
(visceral fat) is found to be one of the risk factors for T2DM, HT, dyslipidemia and CVD [19, 
20]. Visceral adipose tissue is also the fat depot in which is in close proximity of the hepatic 
portal circulation, a factor that might explain the link between visceral fat and metabolic 
disturbances [15, 18]. The two adipose tissue sites were investigated in this thesis in order to 
possibly detect a difference in terms of infiltrating cells. 
1.2.5 Identification of inflammatory factors  
In order to identify infiltrating immune cells in selected adipose tissue of obese patients, 
various markers of T-, B lymphocytes and macrophages, as well as for natural killer (NK) 
cells were investigated since these cells are important in the immune response and thought to 
be involved in the low grade inflammation occurring in obesity. Previous studies have 
quantitatively investigated the heterogeneous cell population found in adipose tissue using 
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flow cytometry and immunohistochemistry (IHC), hence were the chosen methods for this 
master thesis [16, 21, 22, 27, 34]. 
1.3 Treatments of obesity 
As the prevalence of overweight and obesity is increasing, so are the demands for treatment 
methods where sustainable weight loss and lifestyle change are achieved. Fad diets have been 
around for decades, such as the Atkins Diet, the South Beach Diet, the Blood Type Diet, and 
health “gurus”, such as Grete Roede and Fedon Lindberg, have promoted their ideas to 
combat overweight. However, for a person who is morbidly obese, more comprehensive help 
and serious alternatives are needed. 
1.3.1 Conventional therapy 
Ebeltoft Kurcenter in Denmark was established in 2001 and was perhaps the first 
conventional treatment program available for morbidly obese in the Nordic countries. The 
leading focus here was lifestyle change and weight loss through exercise and strict diet. The 
stay was of a length of 15 weeks and a study has shown that the participants experienced an 
improvement in oral glucose tolerance tests and in the blood lipid levels. The weight loss was 
similar to what can be seen after surgical treatments [35]. Similar treatment centers have been 
developed in Norway the past years, such as Evjeklinikken, Røros Rehabilitation Center, 
Tonsåsen Rehabilitation and Alm Center (Molde), where weight loss is accomplished through 
exercise, healthy diet and behavioral therapy. The length of stay varies depending on the 
centre and most of these are connected to the leading hospitals in Norway.  
Personal experience has been acquired at Røros Rehabilitation Centre by working there as a 
dietitian on the obesity team. This team consisted of physical activity therapists, nurses and a 
dietitian, working closely with a psychologist. One of the main reflections from my weeks of 
involvement was that the participants were not at Røros Rehabilitation Centre solely due to a 
sedentary lifestyle and unhealthy eating habits. The weight gain was rather an outcome of past 
events in which had contributed to psychological difficulties, therefore the competence of the 
psychologist was indispensible. The participants’ degree of success throughout the stays at the 
center was not defined by weight loss, but rather their physical and mental state, their 
openness to change and the integration of the newly introduced habits for their home stay. 
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Although not resolved, the participants experienced an improvement in metabolic disorders 
such as T2DM and HT, steady weight loss and improved physical and mental health. This 
conventional management of obesity is a valuable alternative to surgical treatments of 
obesity. 
1.3.2 Bariatric surgery 
Oslo University Hospital Aker, Vestfold Hospital, Voss Hospital and Nordland Hospital Bodø 
are some of the several leading hospitals in Norway that perform surgical treatments of 
obesity. Bariatric surgery, the term used collectively for surgeries which have the intention of 
treating severe obesity in patients who have failed other attempts of weight loss and who are 
at serious risk of developing a number of diseases related to the obesity [36, 37]. When 
undergoing bariatric surgery, the obese patient is closely followed-up pre- and post surgery by 
an interdisciplinary team in order to achieve success and maintained weight loss.  
Of the bariatric surgeries, the one performed the most in Norway is gastric bypass [38]. 
Findings in the literature show that 68.2% of the excess body weight was lost after a gastric 
bypass surgery, whereas 25% of the total body weight is lost 10 years after the surgery [39, 
40]. The bariatric surgeries of interest for this thesis were biliopancreatic diversion with 
duodenal switch surgery and laparoscopic gastric bypass. 
 
Figure 1.4. Diagram showing the outline of gastric bypass surgery. Figure taken from Aasheim, Mala et al. 
2007 [38]. Gastric bypass is in short a 95% reduction of the stomach achieved by stapling the stomach which 
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becomes re-attached the lower part of the small intestine, called the Treitz’ ligament. The lower part of the small 
intestine is from below the duodenum and is called the Roux-limb. The Treitz’ ligament is the new opening of 
the gastric pouch to the rest of the intestines. The biliopancreatic duct is connected to the Roux- limb about 40 
cm below the Treitz’ ligament, creating the common duct, in which food and digestive juices rejoin before the 
digested food carries on into the large intestines. 
The main aim for this operation is the significantly decreased stomach size and the shortened 
absorption length for the nutrients [38, 41].  
Out of the various approaches developed in order to combat obesity, studies have shown that 
bariatric surgery is the only way in which T2DM [40], metabolic syndrome, HT and sleep 
apnea are resolved; all consequences linked to obesity [36, 38]. Bariatric surgery affects the 
immunological response, which explains the resolution and improvements of the metabolic 
disturbances due to the reduction in inflammatory factors, originating from the pathogenic 
adipose tissue [42]. No other weight loss method achieves the same reduction of metabolic 
disorders. In addition to this, a systematic review found that obesity surgery does not lead to 
significant psychological problems, but rather an improvement in psychological status [43]. 
Quality of life has also been found to be improved [44]. 
For an overweight or obese person taking the step towards a healthier life style in which 
includes altered eating habits and increased physical activity, whether it is a conventional 
method or bariatric surgery, professional health care workers are necessary in the path to 
success, with the emphasis on resolving psychological issues in order to achieve the desired 
weight loss [45-48]. 
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2 Aims and objectives 
Based on what has been described above it is commonly accepted that obese patients suffer 
from proinflammation and possibly infiltration of immune cells in the WAT. To determine if 
WAT from obese patients harbored infiltrated immune cells we initiated a pilot study. In this 
study we wanted to examine omental and subcutaneous fat of two populations of patients. For 
the first population (11 patients) we aimed at examining prior to and one year post bariatric 
surgery for cells infiltrating WAT. The other population (5 patients) we wanted to examine 
for infiltrating cells prior to bariatric surgery. For both populations we aimed at analyzing 
WAT for infiltrating cells by histology and IHC. For the latter population we also wanted to 
fractionate infiltrating cells followed by flow cytometry analysis. In order to perform 
fractionation we aimed at optimizing a method for gravimetric purification of cells infiltrating 
WAT. 
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3 Materials 
Cell fractionation 
Products Supplier Catalog number
Sterile Stainless Steel Surgical Blade Paragon 4867-1023 
Filter holder 25 mm Easy Pressure for 
syringe
PALL Life 
Sciences
PALL4320
O ring Viton PALL Life 
Sciences
PALL83475
Spectra Mesh Nylon Filter 200µm 
pores, 125µm thickness
Spectrum 
Laboratories Inc.
SPEC 148116
Sterile Syringe (10 ml) Luer BD Plastipak REF 302188 Lot: 
4196774
Liberase TM Research Grade Roche 5401119001
HBSS GIBCO 14025-050
BSA US Biological 
(Biosite Norway)
A1311
 
Lysis 
Products Supplier Catalog number
Lysis buffer Sigma R7757
HBSS GIBCO 14025-050
BSA US Biological 
(Biosite Norway)
A1311
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Flow cytometry 
Products Supplier Catalog number
PS- Micro plate. Sterile, V-shape Greiner Bio-one 651161
PBS tablets Sigma P4417-100TAB
BSA US Biological 
(Biosite Norway)
A1311
FITC Conjugated Anti-Human CD-56 eBioscience 11-0569-71
FITC Conjugated Anti-Human CD-14 eBioscience 11-0149-71
Monoclonal Mouse Antihuman 
CD4/FITC
DAKO F0766
Monoclonal Mouse Antihuman 
CD8/FITC
DAKO F0765
Mouse IgG/FITC DAKO X0927
CD19/FITC BD-Becton 
Dickinson
345776
 
Sectioning of adipose tissue 
Products Supplier Catalog number
Formalin Buffered 10% Chemi-teknik 21154
Di-sodium hydrogen phosphate water free Chemi-teknik 28026-292
Sodium hydrogen sulphate (monohydrate) Chemi-teknik 28120-231
Distilled water SIGMA 95284  
Immunohistochemistry 
Products Supplier Catalog number
Distilled water SIGMA 95284
Citrate buffer SIGMA C2488
PT link (Target Retrieval Solution, pH 9 
(10x), 3-in-1)
DAKO S2375
Proteinkinase K Prediluted DAKO S3020
Wash buffer TBS DAKO S3006
Dilution Buffer DAKO S0809
HRP- Peroxidase Blocking DAKO S2023
Visualization system EnVison- DAB+ DAKO K5007
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Software 
Software Supplier
CellQuest for Macintosh Becton Dickinson
Cytobank Stanford University
Microsoft Office XP Microsoft Corporation
PASW Statistics 18 SPSS Inc.
Endnote Thomson Reuters  
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4 Methods 
4.1 Ethics statement 
After being informed about the study, its purpose and the subject’s legal rights, each enrolled 
subject returned a written consent form. The study was approved by the Eastern Norway 
Regional Committee for Medical Research Ethics (REK). 
4.2 Biochemical Analyses 
4.2.1 Blood samples obtained from patients donating adipose 
tissue at HUH 
At the commencement of the study “Switch from Stress Response to Homeobox Transcription 
Factors in Adipose Tissue after Profound Fat Loss” by Dankel et al. [49], blood samples and 
anthropometric measures were obtained from all participating patients, the obese and the 
controls. All blood samples were taken while fasting and before the surgery. For the obese 
patients, additional blood samples and anthropometric measures were obtained at follow-up 
one year after the surgery. 
4.2.2 Blood samples obtained from patients undergoing gastric 
bypass at OUHA 
A specific blood analysis was created for the included subjects in the Intrafat study (see 
appendix 1). This specific requisition included an extensive range of blood values, including 
glucose, insulin, HbA1C, triglycerides, total-,high density lipoprotein (HDL)- and low density 
lipoprotein (LDL)- cholesterol (parameters not included in the general blood test). Patients 
who qualify for gastric bypass, whether or not included in the study, have a general blood test 
taken two weeks before the surgery and a screening on the day of the surgery at OUHA. 
Intentionally the 5 included subjects were meant to have the Intrafat blood analysis done in 
addition to the screening on the day of surgery; however it was only conducted on 2 of them. 
This resulted in having to use the blood tests from two weeks prior to the surgery for three of 
the subjects when analyzing the results. 
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4.3 Isolation of cell fractions in adipose tissue 
Fractionation of fat samples was performed according to the method developed and described 
in the result section. 
4.3.1 Red blood cell lysis 
The following steps were built upon: “The protocol for separation of lymphocytes from 
mouse spleen and lymph nodes”. The tube with the SVF solution was centrifuged at 585 x g 
for 5 minutes and once the supernatant was removed the pellet was resuspended in 200 µl red 
blood cell (RBC) lysis buffer (ACT buffer, Sigma R7757) and incubated for 2 minutes at 
room temperature (RT). After incubation, the lysis was stopped by adding 800 µl Hank’s 
buffered salt solution (HBSS) containing 5% bovine serum albumin (BSA) and the solution 
gently mixed. The tube was then centrifuged at 382 x g for 7 minutes and the pellet was 
resuspended with 500 µl HBSS 5% BSA.   
4.3.2 Flow cytometry 
The flow cytometry method was optimized on analysis of peripheral blood lymphocytes 
(PBL) (Ullevål University Hospital). The protocol was modified to be used for one layer 
staining. The flow cytometer was from Becton Dickinson and was a FACSCalibur; the 
software used was Cell Quest, which was also delivered by Becton Dickinson, as well as 
Stanford CytoBank developed by Stanford University. 
In short the method was as followed: 
1) The eppendorph tube containing the SVF solution was filled with cold phosphate 
buffered saline (PBS), ~ 1 ml  
2) Centrifuged for 7 min at 478 x g  
3) The cell pellet was resuspended in cold PBS, ~1 ml 
4) Centrifuged for 7 min at 478 x g  
5) The pellet was resuspended in dilution solution (PBS 1% BSA) 
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6) 5 µl one layer antibodies were added to each well of a 96 well micro plate 
Table 4.1. Antibodies selected for the flow cytometry. The antibodies were primarily conjugated to fluorescein 
isothiocyanate (FITC). 
Used Antibody for: Type of marker:
Negative control Mouse IgG1
CD4 T cells
CD8 T cells
CD14 Monocytes and macrophages
CD19 B cells
CD56 Natural killer cells  
7) 45 µl of cells /0.5-1.0x10
6
 mill cells /mL) were added to each well 
8) The micro plate was placed in refrigerator for minimum 30 minutes 
9) The wells were filled with cold PBS and centrifuged at 478 x g for 5 minutes.  
10) The PBS was removed and resuspended gently using vortex on the tray 
11) The wells were filled with cold PBS and centrifuged at 478 x g for 5 minutes 
12) The PBS was removed 
13) The cells resuspended in 50 µl dilution solution 
The amounts of the antibody displaying immune cells were investigated using the flow 
cytometer and the software Cell Quest. The same software was used for analyzing the results, 
as well as the software CytoBank. 
4.4 Histology 
4.4.1 Adipose tissue biopsies from patients from HUH 
Adipose tissue biopsies (approximately 1 gram) were received from HUH and stored on dry 
ice. This was tissue from a selection of obese patients and control persons who had been 
included in a study between 2003 and 2007. Biopsies received were all fixated in 
formaldehyde and were further treated at the Pathological Department at Rikshospitalet HF. 
Blood test results were also received for all patients. 
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The original patient identifications created for the biopsies from HUH remained when further 
working on the biopsies in Oslo. 
4.4.2 Fixation of adipose tissue biopsies 
The adipose tissue biopsies were individually fixed in 1.6 ml 4% paraformaldehyde at the 
laboratory, then further dehydrated, paraffin embedded and finely sectioned (0.2 µm)  by the 
Pathological Department at Rikshospitalet HF.  The sections were placed onto individual 
microscope slides, and the sections stained with hematoxylin (HE). 
4.4.3 Adipose tissue biopsies from patients from OUHA 
A subcutaneous and one abdominal biopsy (same location as the biopsies for the 
fractionation) were directly immersed in separate tubes of 15 ml formaldehyde when the 
tissue was removed from the patients, this for histology. These biopsies were treated identical 
to the tissue biopsies from HUH. 
4.4.4 Immunohistochemistry (IHC) 
IHC is a widely used procedure performed to detect various proteins present in biological 
tissue by the use of antibodies. The antibodies are conjugated to an enzyme that will elicit a 
type of excitation producing a color, visualizing antigen-antibody interaction.  
The immunohistochemistry was performed at the Pathologic Department at HUH and they 
used antibodies conjugated to 3,3-diaminobenzidine (DAB), which is the chromomeric 
substrate for peroxidase. Peroxidase is an enzyme conjugate that will upon the localization of 
antibody-bound antigenic sites elicit a colored reaction. If an antibody reaction occurred, it 
was in this case stained brown [50, 51]. The markers for cluster differentiation 3 (CD3), 
CD20 and CD68 were used in this project. 
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Table 4.2. The markers selected for the immunohistochemistry. IHC was performed on the biopsies 
displaying infiltrating cells from the obese patients and the biopsies for the control patients received from HUH, 
the biopsies from the first two patients from the gastric bypass operations at OUHA, gastric bypass1 (GB1) and 
GB2. 
Used Antibody for: Type of cells:
CD3 T cells
CD20 B cells
CD68 Monocytes/macrophages  
From the observations through the microscope, the biopsies showing infiltrating cells were 
sectioned onto super-frost slides. The biopsy blocks for the control patients were also 
included in the IHC. With ten consecutive samples (marked 1-10) of each biopsy it was 
possible to detect the depth of the infiltration and the position of the infiltration. The super-
frost slides were packed back to back in aluminum foil and stored at -80 ºC until needed, and 
then thawed in RT before the IHC. 
For each selected adipose tissue biopsy, three super-frost slides were used for each antibody, 
and seeing that three antibodies were used, a total nine slides were used per adipose tissue 
biopsy. Example: For 4 A2 super-frost slides 1-10, 1-3 were stained with CD3, 4-6 were 
stained with CD20 and 7-9 were stained with CD68, this for all biopsies.  
The super-frost glasses were de-paraffinised, and processed for antigen retrieval in a 
microwave processing lab station. 
IHC procedure 
In short, these are the steps that were conducted when staining the slides with antibodies to 
the IHC that was performed at HUH. 
1. The slides were incubated at 50 ºC overnight. 
2. The slides were then either heated in a microwave or a PT-link (DAKO). If a 
microwave was used the steps were as follows: the slides were heated at 850W for 9.5 
min, at 400W for 15 min, and rested in 15 min. For the PT-link the slides were 
inserted when the PT-link was heated to 65ºC and slides were kept in the PT-link for 
20 min while the temperature was increased to 97 ºC, before temperature was reduced 
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to 65 ºC, cooling the slides. (For both methods, Envision FLEX Target Retrieval 
Solution is used). 
3. The slides were rinsed in washing buffer (TBS 1:10) 
4. Slides placed in the DAKO Autostainer machine 
5. The selected antibodies were applied and were on for 30 min in RT, washed with 
buffer 
6. Peroxidase blocking for 5 min, washed with buffer 
7. Envision for 30 min, washed with buffer 
8. DAB for 2x5 min, washed in distilled water 
9. Standard staining with HE for 2 min. 
10. Washed in distilled water for about 8 min, then dehydrated in alcohol, xylene. 
11. Cover slides applied in the machine of Sacura Tissue Tek. 
Samples ready for microscopic observation.  
The slides were returned to the Department of Pathology Rikshospitalet HF and investigated 
semi-quantitatively through a microscope and photographed in order to detect CD3, CD20, or 
CD68 positive cells. 
4.5 Statistical analyses 
For the differences between the anthropometric- and biochemical data of the patient group 
and the control group independent samples T tests and paired samples T tests were performed. 
All statistical analysis was performed with PASW Statistics 18. All analysis were set to P= < 
0.05 significance level. 
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5 Results 
5.1 Patient inclusion 
5.1.1 Adipose tissue biopsies of received from HUH 
The inclusion criteria for the obese patients included in the Dankel et al. study [49] were BMI 
> 45 kg/m
2
 (morbid obesity) and Norwegian Caucasian origin. The inclusion criteria for the 
controls were good health, BMI < 27 kg/m
2
 and no history of drug abuse or disorders. For the 
obese patients, the adipose tissue was collected during the bariatric surgery, biliopancreatic 
diversion with duodenal switch, and for the controls, during hernia repair. In addition, of the 
adipose tissue, blood tests were also collected for all of the patients. 
The anthropometric and the biochemical data for the obese patients and controls from Bergen 
included in the adipose tissue biopsy part of the project are shown in the tables below. 
The patient information refers to the order of when the adipose tissue was taken, 1 being the 
first and so on. A1 refers to “Adipogen”, the name of the project at HUH. Number 1 means 
the first round of biopsies taken, respectively from patients at Førde Hospital, A2 being tissue 
from patients at Haraldsplass Hospital. 
Eleven obese patients and three controls were included in the histology part of the project. 
Table 5.1. Anthropometric data for the obese patients at inclusion 
Patient 4A1 7A1 10A1 11A1 16A1 23A1 24A1 25A1 27A1 28A1 30A1
Sex F F F M M F F F M F F
Age 35 57 42 57 59 26 56 30 23 30 35
Weight (kg) 149 120 178 135 177 157 161 141 206 132 145
BMI (kg/m
2
) 48 49 59 58 51 51 58 52 54 47 53  
The average age of the eleven obese patients was 40.9 years old. The average body weight 
was 154.6 kg and the average BMI was 51.5 kg/m
2
. The average BMI for the obese patients 
was above the BMI range for morbidly obese (> 40 kg/m
2
) (Table 1.1). 22.3% of the obese 
patients were male, and 77.7% were female. 
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Table 5.2. Anthropometric data for the controls 
Patient 4A2 20A2 27A2
Sex F F M
Age 27 55 54
Weight (kg) 75 67.8 69.2
BMI (kg/m2) 24.8 23.2 22.3
 
The controls had an average age of 45.3 years old, the average body weight was 70.7 kg and 
an average BMI was 23.4 kg/m
2
. The average BMI was within the normal range < 24.9 kg/m
2
. 
One of the three controls was a male. 
 
Table 5.3. Biochemical data for obese patients at inclusion. Reference ranges from: Fürst 2008, Dietitian’s 
Pocket Book  2006 [52, 53] 
ID: 4A1 7A1 10A1 11A1 16A1 23A1 24A1 25A1 27A1 28A1 30A1
Measure: Reference:
S-
cholesterol
< 4.5 
mmol/L 5.9 3.9 4 4 4.1 5.2 5.7 4.6 4.5 3.7 5
S-LDL
≤ 1.8 
mmol/L 4.2 2.5 2.7 2.6 2.8 3.9 3.8 3.4 3 2.6 3.1
S-HDL
F: ≥ 1.2 , M: 
≥ 1.0 
mmol/L 1.4 1.1 1.1 1.1 1 0.8 0.9 0.9 0.9 0.8 1.5
S-TG
< 1.7 
mmol/L 1.4 1.4 1.2 1.3 1.4 2.5 1.9 1.5 1.4 1.4 2.1
Fasting 
glucose 
< 6.0 
mmol/L 5 6.2 7.6 6 10.6 8.7 7.9 5.2 5.8 5.8 5.5
Insulin < 11mU/L 11 5.8 57.5 15.5 17.2 29.3 33.5 18.2 20.2 64.6 12.8
Insulin C-
peptide 
0.3-1.2 
nmol/L 0.8 0.2 0.3 1.4 0.5 2.3 1 1.8 1.6 2.2 1.1
CRP < 5 ml 20 5 29 5 6 11 11 8 15 19 14
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Table 5.4. Biochemical data for the controls at inclusion 
4A2 20A2 27A2
S-cholesterol < 4.5 mmol/L 3.9 5.1 5.9
S-LDL ≤ 1.8 mmol/L 2.7 3.3 3.8
S-HDL
F: ≥ 1.2, M: ≥ 
1.0 mmol/L 1.2 1.4 1.8
S-TG < 1.7 mmol/L 0.9 1.2 0.9
S-Insulin < 11mU/L 3.1 6.7
S-Insulin
C-peptide 0.3-1.2 nmol/L 0.4 0.9
S-CRP < 5 ml 1 6 < 1
 
Comparison of the anthropometric and biochemical data of the obese patients 
and the controls from HUH 
When comparing the anthropometric data for the obese patients to the controls at inclusion 
(Table 5.1 and 5.2), there were significant difference between the body weights (P= < 0.005), 
and hence the BMI (P= < 0.005). 
When comparing the biochemical data for the obese patients to the controls at inclusion 
(Table 5.3 and 5.4), no significant difference in the total cholesterol level (P= 0.604), the 
LDL cholesterol (P= 0.759) or the HDL cholesterol (P= 0.124) were found. However, it was 
found that the obese patients had significantly higher average triglyceride (TG) level when 
compared to the controls (P= 0.004). 
The fasting glucose level was not obtained for the controls. The average fasting glucose level 
for the obese patients was 6.8 mmol/L, this average value indicates impaired glucose 
tolerance [53]. 
The average insulin level for the controls was 4.9 mU/L and 25.9 mU/L for the obese patients. 
When comparing the insulin values, there was significant difference between the insulin level 
of the obese patients and the controls (P= 0.005). Whereas there was not found a significant 
difference in the insulin C-peptide between the two groups (P= 0.214).  
The average CRP value for the controls was 2.7 mg/L and it was under the reference value 
which is < 5 ml [53]. The CRP values for the obese patients were considerably higher than the 
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controls, with an average of 13 ml. The obese patients had significant higher CRP levels 
compared to the controls (P= 0.004).
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5.1.2 Anthropometric and biochemical data for bariatric surgery patients at inclusion and 1 year post 
surgery  
Table 5.5. Anthropometric and clinical data for the obese patients pre and post surgery. Blood tests were obtained fasting, and post surgery blood tests were taken one 
year after the surgery 
ID: 4 A1 7 A1 10 A1 11 A1 16 A1 23 A1 24 A1 25 A1 27 A1 28 A1 30 A1
Measure: Reference: Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
Sex (M/F) F F F M M F F F M F F
Age 35 36 57 58 42 43 57 58 59 60 26 27 56 57 30 31 23 24 30 31 35 36
Weight (kg) 149 103 120 64 178 103 135 73 177 143 157 109 161 107 141 69 206 122 132 75 145 96
BMI at 
inclusion 
(kg/m2)
18.5-24.9 
kg/m2
48 35 49 37 59 36 45 24 51 41 51 35 58 39 52 25 54 32 47 26 53 35
S-kol < 4.5 mmol/L 5.9 4 3.9 3.4 4 2.5 4 3.5 4.1 3.7 5.2 3.5 5.7 4.1 4.6 2.8 4.5 2.4 3.7 3.9 5 3
S-LDL ≤ 1.8 mmol/L 4.2 2.4 2.5 2.2 2.7 1.3 2.6 2.3 2.8 2.6 3.9 2.4 3.8 3.0 3.4 1.9 3.0 1.2 2.6 2.4 3.1 1.4
S-HDL
F: ≥ 1.2 , M: 
≥1.0 mmol/L 1.4 1.5 1.1 1 1.1 1.1 1.1 1 1 0.8 0.8 0.8 0.9 0.8 0.9 0.8 0.9 1.1 0.8 1.1 1.5 1.3
S-TG < 1.7 mmol/L 1.4 0.7 1.4 1 1.2 0.71 1.3 0.9 1.4 1.4 2.5 1.5 1.9 1.75 1.5 0.7 1.4 0.52 1.4 2.1 2.1 1.3
Fasting glucose 
(mmol/L)
< 6.0 mmol/L
5 5.6 6.2 4.6 7.6 6.5 6 4.5 10.6 6.3 8.7 4.9 7.9 6 5.2 4.7 5.8 5 5.8 4.8 5.5 4.9
Insulin (U/L) < 11mU/L 10.6 3.2 5.8 7.2 57.5 7.6 15.5 < 2 17.2 4.5 29.3 11.3 33.5 4.3 18.2 3.1 20.2 3.8 64.6 6.7 12.8 4.4
Insulin C-
peptide 
(nmol/L)
0.3-1.2 
nmol/L
0.8 0.4 0.2 0.9 0.3 0.8 1.4 0.2 0.5 0.7 2.3 1 1 1.2 1.8 0.5 1.6 0.4 2.2 0.81 1.1 4.8
CRP < 5 ml 20 5 5 6 29 6 5 5 6 1 11 1 11 2 8 3 15 2 19 5 14 1
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Comparison of the anthropometric and biochemical data; pre and post surgery 
for the obese patients 
The average body weight for the obese patients was 154.6 kg at time of inclusion and 96.7 kg 
post surgery, this was a significant weight loss (P= < 0.005). Weight loss is accompanied with 
a reduction in BMI, it was a significant reduction in BMI in these patients (P= < 0.005), from 
an average on was 51.4 kg/m
2
 pre surgery to 33.2 kg/m
2
 post surgery. 
There was a significant reduction (P= < 0.005) in the serum cholesterol. There were also a 
significant reductions in LDL cholesterol (P= < 0.005) and TG (P= 0.015). It was however no 
significant change in the HDL level. The HDL level is expected to increase as the lipid profile 
becomes more favorable.  
There were experienced significant reductions in the average fasting glucose level (P= 0.006) 
and the insulin level (P= 0.004). However there was no significant change in the insulin C-
peptide (P= 0.771). 
The average CRP value was distinctly reduced, from an average of 13.0 ml pre surgery, to an 
average of 3.4 ml post surgery. There was a significant reduction (P= 0.001).
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5.1.3 Adipose tissue biopsies received from OUHA- Intrafat pilot 
study 
The patients included in the Intrafat pilot study were randomly selected, 2 of them at the day 
of surgery and the last 3 were included at the preoperative clinic. Patient identification was 
noted as GB (gastric bypass) and 1-5, for being the first to the fifth patient. The criterion for 
these patients was that they were eligible for gastric bypass surgery.  
 
BMI > 40 
BMI > 35-40 with serious co-morbidity such as: 
- Cardiopulmonal condition 
- Insulin treated DM Type 2 
- Poorly controlled hypertension 
- Arthritis 
- Sleep apnea 
Age 18-60 yrs 
No alcohol or prescription drug abuse 
No psychological disorder 
Be motivated 
Self understanding regarding the seriousness of situation 
and ability for behavioral change 
Completed other diets and weight loss programs 
 
 Figure 5.1. The criteria for patient inclusion for bariatric surgery are included in the diagram above. 
Persons with BMI > 40 kg/m
2
 or BMI 35-40 kg/m
2
 with co-morbidities, as well as being 18-60 years, not having 
alcohol or drug abuse, no diagnosed psychological disorder, being motivated and realizing the seriousness of the 
situation, in addition to having completed other weight loss programs are eligible for gastric bypass surgery. 
From NIH conference 1991[54]. 
When receiving tissue from gastric bypass patients at OUHA, adipose tissue was collected 
from a total of 5 patients. Out of these 5, four of these patients were females (80%) and one 
was male (20%).  
38 
 
 
 
The patients included in the Intrafat pilot study had blood tests taken. Due to complications 
only 2 (GB3 and GB5) of the 5 included patients had a the Intrafat blood tests taken on the 
day of surgery, the blood test results from the other patients were obtained from a blood test 
taken at the preoperative clinic, approximately 2 weeks before the surgery. Weight and BMI 
values were noted on the day of the preoperative clinic.  
The patients included donated blood tests and adipose tissue on the day of the operation. 
Table 5.5. Biochemical data for the bariatric surgery patients at inclusion of the Intrafat pilot study. The 
blood reference values are obtained from OUHA standards. 
ID: GB1 GB2 GB4
Measure: Reference:
Sex (M/F) M F F
Age (yrs) 36 37 35
Weight 
(kg) 201 124 122
BMI at 
inclusion 
18.5-24.9 
kg/m2 58 46 45
Fasting 
glucose 
< 6.0 
mmol/L 6.1 5.7 6.7
CRP 0-9 mg/L 6 6 5
 
The average BMI was 49.7 kg/m
2
 and this was significantly higher than the upper 
recommended level of 24.9 kg/m
2
 (P= 0.017) (Table 1.1). 
The average fasting glucose level for the patients GB1, GB2 and GB4 was not significantly 
elevated when compared to the high end of the recommended value (P= 0.801). Insulin level 
was not obtained in this blood test. None of these 3 patients had elevated CRP level. 
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Table 5.6. Biochemical data for the patients who had the Intrafat blood test taken at the day of surgery. 
The blood reference values are obtained from OUHA standards. 
ID: GB3 GB5
Measure: Reference:
Sex 
(M/F) F F
Age 48 60
Weight 
(kg) 125 117
BMI at 
inclusion 
(kg/m2)
18.5-24.9 
kg/m2
44.5 38
S-kol < 4.5 mmol/L 4 4.1
S-LDL ≤1.8 mmol/L 1.5 1.7
S-HDL
F: ≥ 1.2 , M: 
≥ 1.0 mmol/L 0.78 1.48
S-TG < 1.7 mmol/L 3.9 2.1
Fasting 
glucose 
(mmol/L)
< 6.0 mmol/L
5.9 6.7
Insulin < 11 mU/L 85.4 10.9
Insulin C-
peptide 
(pmol/L)
370-1470 
pmol/L
4906 1387
HbA1c 4-6% 5.8 5.9
CRP 0-9 mg/L 3 4
 
The Intrafat blood analysis was used for patients GB3 and GB5. The S-HDL value was low 
for patient GB3, and the S-TG was above the recommended level. The fasting glucose levels 
for the 2 patients were not significantly higher than the upper recommended level (P= 0.531). 
However the insulin level for patient GB3 was 7 times higher than the upper recommended 
level, and had a C-peptide level 3.5 times higher than the upper end of the reference range. 
Surprisingly the same patient had a normal HbA1c. These two values were normal for patient 
GB5. The CRP values were within the normal range.
40 
 
 
 
5.2 Method development 
Pre- and post surgery fat biopsies from obese patients (subcutaneous and omental fat) and pre 
surgery fat biopsies from control persons (subcutaneous fat) were analyzed for infiltrating 
non-fat cells by flow cytometry and histology. Figure 5.2 illustrates the flow of the regime 
and how the isolation and the identification of the non-fat infiltrating cells in the adipose 
tissue were conducted. 
Adipose tissue
Isolation of 
infiltrating 
cells
Histology
Fat Infiltrating 
cells
Differential 
counting
Flow cytometry
a) PBL
b) SVF
 
Figure 5.2. Schematic representation of the flow sheet on how fat biopsies were handled in order to be 
analyzed by flow cytometry and histology. For the obtained adipose tissue, one piece underwent enzymatic 
digestion for further isolation of the infiltrating cells, where the fat was removed and the infiltrating cells were 
counted and investigated using flow cytometry. A second piece of the tissue was fixated, stained with HE and 
sectioned for further investigation through microscope and the use of IHC for some of the tissue samples. 
 1 A 
2 
3 
4 
1 B 
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5.2.1 Isolation of infiltrating cells (1A in Figure 5.2) 
The original method 
In order to quantify and identify the infiltrating cells in WAT of obese patients, we aimed at 
optimizing a method in which non-fat infiltrating cells were isolated from fat tissue. These 
cells are found in the SVF of adipose tissue [14, 15].  The infiltrating cells are also called the 
SV cells. Using a gravimetric principal where cells were released from the fat tissue by 
enzyme digestion followed by cell separation through centrifugation, the cells could be 
counted in a Beckman Coulter ACT differentiation counter and quantified using flow 
cytometry.  
We optimized a method that was originally developed at the University of Bergen (UiB). 
Hence, I was initially introduced to the fractionation method developed by PhD candidate 
Simon Dankel at HUH, [55, 56].  
In short the method was as follows (step 1 to 11): 
1) Fat tissue was collected in a tube containing PBS supplemented with 0.1% BSA at RT. 
2) Prior to use, the fat tissue was rinsed in PBS 
- To remove surface blood contaminants. 
3) Next, the tissue was cut into small pieces (0.5 to 1 g) and further homogenized by 
further cutting.  
- This was done to obtain small pieces for the digestion to be optimal. 
4) The pieces were mixed with Collagenase and Liberase Blendzyme 3 (LB3) dissolved 
in PBS with 0.1% BSA (LB3, is designed to replace most "high quality" lots of 
traditional collagenase).  
5) Mixing of enzyme was performed to ensure optimal digestion and the samples were 
incubated at 37 °C for 30 min in a humidified atmosphere, and shaken at 50 
revolutions per minute (rpm) or 80 rpm orbital.  
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- Incubation at 37 °C with shaking was necessary in order to have optimal enzyme 
effect.  
6) After incubation the samples were filtered into centrifuge tubes through a nylon filter 
using a syringe and filter holder. The samples were then left to separate, with 
adipocytes floating to the top. 
Optimal separation of fat (floating) and infiltrating cells (in liquid phase) was initially 
tested by simply letting the centrifuge tube stand on the bench (A). If this was not 
successful the samples would then be centrifuged for 1 min at150 x g (B). The fat cells 
would then be at the top and infiltrating cells in the buffer solution.    
7) Independent if A or B was successful, the top phase (fat cells) was pipetted out, mixed 
with PBS and centrifuged at 150 x g for 1 minute before transferred to a new 
eppendorph tube where lysis buffer was added. The fat cells were stored separately (on 
ice) until the infiltrating cell sample had been analyzed. 
- Samples would be stored for further fractionation if needed. 
8) The filter would have unresolved matrix on it which was scraped off and added to the 
centrifuge tube with the SV cells. The filter was also added to this tube. The tube was 
centrifuged at 150 x g for 10 minutes.  
9) After centrifuging, the filter and the supernatant were removed. The pellet was 
resuspended in lysis buffer or PBS if analyzed by flow cytometry and stored on ice. 
10) If a separate matrix-fraction was desired, the matrix leftovers were transferred to a 
centrifuge tube, with the filter, where pure PBS was added. This was shaken carefully 
and centrifuged at 150 x g for 3 minutes. The matrix was transferred to an eppendorph 
tube and lysis buffer was added.  
- This was done at 4°C (ice) and performed to homogenize the matrix tissue.  
11)  Infiltrating cells would be analyzed by flow cytometry. 
- To analyze for the relative number of T-, B-, NK- cells as well as monocytes and 
macrophages. 
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Optimizing and establishing of the fractionation method at the University of 
Oslo (UiO) 
At the UiO we aimed at optimizing the method in order to isolate infiltrating cells with 
optimal yield. We initiated the optimization by using adipose tissue from deceased patients 
from the Pathological Department at Rikshospitalet HF.  The method was performed 14 times 
before the harvesting of adipose tissue from OUHA could commence. RM1- RM14 was the 
identification code for the fractionations completed on tissue received from the pathological 
department. The tissue was identified as RM1-RM14, denoting Rettsmedisinsk sample 1, 
2….-14.  
We did not perform flow cytometry on the tissue from the Pathological Department, as we 
found this irrelevant as long as this was pathological tissue. Despite this, we considered it 
useful to use such tissue in order to optimize the method quantitatively.  
Optimization of the method was performed in a fume hood under sterile conditions, and the 
equipment was endotoxin- and nuclease free in order to reemploy the way the method should 
be executed with genuine patient materials.  
The first steps (1-4) were more or less identical in the two methods. However, collagenase 
Liberase Blendzyme medium thermolysin (LBTM) was replaced for LB3 since LB3 was out 
of production. LBTM was chosen since it was considered equally good as LB3. The 
concentration of LBTM was initially 26 Wünsch units/vial (collagenase activity) and was 
diluted to a concentration of 2.6 Wünsch units / vial. The enzyme was dissolved in sterile 
HBSS and was aliquoted into 0.5 ml amounts in eppendorph tubes and stored at -20°C. On the 
day of experiment, the enzyme solution was thawed, carefully vortex and mix with a pipette 
10 times.  
Upon collection samples were soaked in 15 ml HBSS 5% BSA in order to rinse the tissue for 
excess blood and other tissue fluids. PBS as was the buffer in the original procedure was 
exchanged for HBSS 5% BSA, since HBSS contains a pH indicator and 5 mM glucose 
yielding more optimal conditions. It should be noted that protocol was optimized for one 
tissue sample. However, it may be preformed for two samples in parallel. In this case one of 
the samples will have to be stored in the HBSS/enzyme solution for some time in the 
incubator cabinet while the other sample is cut into pieces and homogenized. The time of 
incubation in HBSS/enzyme solution should be minimized. 
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Upon arrival with the tissue samples the incubator cabinet was set for 37 °C and the 
centrifuge was fast cooled to 4 °C. 
 
Figure 5.3. Weighing. The adipose tissue obtained was initially larger than what was needed; hence the required 
amount (approx. 1 gram) was weighed out on Petri dishes.  
The adipose tissue biopsies received were approximately 4-5 grams, whereas required weight 
for the fractionation was approximately 1 gram per sample. The tissue was therefore cut to the 
accurate sizes, weighed and noted.   
 
Figure 5.4. Cutting. After weighing, the adipose tissue was cut in a porcelain mortar using scalpels. The tissue 
was cut up until it had a purée-like consistency; this to improve the enzymatic digestion. 
There was some discussion concerning using tissue samples weighing 2-3 grams, however 
when counting the SV cells in the SVF solution using this weight, it showed that the amount 
of white blood cells (WBC) was not significantly (P= 0.217) greater compared to the smaller 
samples (0.7-0.8 gram).  The infiltrating cells are included in the WBC count. 
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Figure 5.5. The diagram showing the weight of the samples and the detected WBCs in the SVF solution for 
the small (RM3, 6, 8, 9, 11, 13, 14) versus the large (RM4, 5, 7, 10, 12) samples.  
The selected tissue was vigorously cut up using a scalpel and a mortar until a paste-like mash 
was achieved. In separate 50 ml NUNC-tubes 3.5 ml of HBSS supplemented with 0.5 mL 
LBTM (2.6 Wünsch units/0.5 ml) were prepared. The cut up tissue samples were added to the 
tube and left in the preheated incubator cabinet until digested. The samples were incubated at 
37 °C for 1 hour in a humidified atmosphere, and shaken at 0.1 x g (80 rpm) orbital. 
 
Figure 5.6. Cut up tissue incubated with HBSS/enzyme solution for enzymatic digestion. In an improvised 
holder for the incubation made from a Styrofoam box and tape. This created a slight angle on the tube, which 
increased the digestion surface and avoided solution in the cap of the tube. 
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After an hour, the incubation was stopped and in case of more than one parallel, one was 
taken out for further treatment. The other parallel sample was left to further incubate without 
shaking at 37 °C. 
The incubation time at this step was 15-30 minutes in the initial protocol. However, we found 
that more time was required for optimal effect and increased the time to 1 hour.   
 
Figure 5.7. Tissue after enzyme incubation. The digested tissue had separated into two layers, the adipocytes 
and undigested matrix floating on top and the SVF solution being the remains of the liquid phase 
One major difference between the method optimized by us and the method developed at UiB 
was that we were interested in the SVF fraction whereas the UiB-method was optimized for 
collection of the fat cell fraction. Hence after the enzyme incubation step in which the 
digested tissue had separated into two layers, the adipocytes that were located at the top were 
removed leaving the SVF solution (liquid phase) in the test tube. In order to isolate cells from 
the SVF fraction the solution was transferred to a 10 ml syringe and sieved through a sterile 
Spectra/Mesh nylon filter in order to remove any undigested matter, called the matrix. The 
matrix consists of connective tissue and blood vessels. 
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Figure 5.8. Removal of undigested matrix by filtration. A syringe was attached to the filter holder on a 
centrifuge tube. The tissue solution was poured into the syringe, pressed through a sterile Spectra/Mesh nylon 
filter. 
 
Figure 5.9. Captured undigested matrix. The Spectra/Mesh nylon filter with captured connective tissue, blood 
vessels and some SV cells. 
After filtration, undigested matrix was left on the Spectra/Mesh nylon filter. The matrix was 
then treated separately to the SVF. To release valuable SV cells embedded in the matrix the 
filter was rinsed three times with 1 ml ice cold HBSS 5% BSA. This was done by carefully 
removing the syringe and opening the filter holder. The undigested matrix was manipulated to 
the centre of the filter using sterile scalpels. Then the filter holder was assembled, syringe put 
back on the filter holder before 1 ml HBSS 5% BSA was poured in the syringe and pressed 
through. This was repeated three times. 
The remaining matrix on the filter was transferred to an eppendorph tube (labeled Ma Sup) 
and 1 ml of ice cold HBSS 5% BSA was added and kept on ice until use. The tube was 
vigorously mixed in order to release any possible SV cells left in the matrix. The SV cells in 
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the matrix supernatant were later counted along with the SV cells in the SVF solution. It 
should be noted that the matrix was not dissolved completely at any time. 
 
Figure 5.10. Digested, filtered and rinsed tissue. After filtration the tissue solution was rinsed with HBSS 5% 
BSA. The remains on the filter was washed with 1 ml HBSS 5% BSA three times in order to reduce the matrix 
matter left on the filter and optimal release the SV cells trapped in the matrix. 
To optimize the time of separation centrifugation of samples were compared to gravimetric 
sedimentation (5 min at 20 °C). However, upon centrifugation (150 x g for 1 min) adipocytes 
were ruptured, in that the fat was smeared on the inside of the tube. In addition, the fraction 
had an overall oily appearance. Based on this it was decided to perform gravimetric 
sedimentation at this step. 
 
Figure 5.11. Gravimetric sedimentation of fat cells. Leaving the tubes to stand on the bench for five minutes 
created two clear layers, adipocytes forming the top layer. 
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5.2.2 Removing the fat from the digested tissue solution (2 in figure 
5.2) 
After separation, the adipocytes (top layer) were removed from the filtered SVF solution 
using a P-1000 pipette. Some SVF solution was unintentionally sucked into the pipette tip 
when taking out the adipocytes, therefore the pipette was let to stand in an empty centrifuge 
tube with tip on for 2 minutes, to let the adipocytes gravimetrically separate from the SVF 
solution trapped in the pipette tip. 
 
Figure 5.12. Adipocyte removal. The pipette used to remove the adipocytes (top layer) from the main SVF 
solution was left to stand in an empty centrifuge tube for two minutes for gravimetric separation of the 
adipocytes trapped in the SVF solution of the pipette tip. 
 
Figure 5.13. Gravimetric separation of fat cells in the pipette. After two minutes, the adipocytes had floated 
to the top of the trapped SVF solution in the pipette tip. The SVF solution was pressed out of the pipette back 
into the main centrifuge tube with the rest of the SVF solution. The adipocytes (remaining in the pipette tip) 
were transferred to a labeled eppendorph tube. 
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The SVF solution free of fat cells was pressed out of the pipette tip back into the main 
centrifuge tube, retaining the adipocytes in the tip. The adipocytes were transferred to a 
separate eppendorph tube. This step was repeated until the SVF solution was completely free 
of adipocytes. Once the top layer was completely removed, the adipocytes were immediately 
frozen at -80°C.   
5.2.3 Infiltrating cells (3 in figure 5.2) 
Once the fat layer had been removed, the SVF solution without the matrix fraction was 
aliquoted into 5-6 eppendorph tubes which were centrifuged at 585 g for 5 minutes at 4 °C. 
The supernatant was collected in one 15 ml centrifuge tube and was frozen directly at -80 °C 
and stored for future use. The cells were washed in 1 ml of HBSS 5% BSA before a second 
round of centrifugation. The supernatant from the second centrifugation was discarded and 
0.5 ml of HBSS with 5% BSA was added to one of the eppendorph tubes. The pellet was 
dissolved in the HBSS and then transferred to the next tube, with the same manoeuvre 
performed on the remaining tubes; resulting in all pellets assembled and dissolved in the last 
eppendorph tube.  
 
Figure 5.14. SV pellet after centrifugation. 
Upon collection the infiltrating cell fraction was contaminated by RBCs. The RBCs were 
removed by lysis as described under material and methods. In short, the pellets were collected 
and centrifuged for 5 min at 585 x g and 4 °C. The supernatant was removed and the pellet 
dissolved in 250µl of RBC lysis buffer, at RT for two minutes. Originally the protocol 
suggested to use Roswell Park Memorial Institute (RPMI) medium 5% fetal bovine serum 
(FBS), but it was decided to continue to incubate SV cells in HBSS 5% BSA. For the tissue 
samples of 1.0 gram, 1 ml RBC lysis medium was used.  
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The cell suspension was centrifuged at 306 x g for 7 minutes. The supernatant was removed 
and the SV cells pellet resuspended in 0.5 ml of HBSS 5% BSA before counting. The tube 
containing the matrix leftovers (Ma Sup) was also prepared for counting. 
The SV cells, from the SVF solution, and the SV cells released from the matrix leftovers (Ma 
Sup) were counted in the Beckman Coulter ACT differentiation counter where the WBCs 
detected were noted. The WBC count indicates the amount of infiltrating cells (SV cells). 
After counting all cell suspensions were frozen at -80°C. 
WBC counting for the adipose tissue from the Pathology Department, 
Rikshospitalet HF 
It should be noticed that for all of the 14 fractionation trials using pathological tissue the 
experiments were discontinued after counting. 
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Figure 5.15. WBCs detected in the SV cells. WBCs from the SVF solution and the SV cells released from the 
matrix (Ma Sup). The WBC counts showed the amount of infiltrating cells in the cell suspensions.  
No data for RM1 and RM2 were obtained as the procedure failed. Furthermore, for RM3, 
RM4 and RM5 the Ma Sups were not counted, whereas the other fractionation results are 
given in the diagrams. RM7 had much greater amount WBCs in the Ma Sup than the SVF 
solution (0.85 million WBC/ml in the Ma Sup vs. 0.4 million WBC/ml in the SVF solution). 
RM12 had a lot greater amount of WBCs compared to the others in the SVF solution, 0.97 
million WBC/ml. Although RM12 is one of the large samples, it was not found a significant 
difference between the small and the large samples (P= 0.217). 
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5.3 Analysis of infiltrating cells of adipose tissue 
from gastric bypass surgery patients, OUHA 
After establishing a method for fractionation of infiltrating cells of WAT, we wanted to 
employ the method on genuine patient materials.  
Table 5.7. The SV cell count from GB3-GB5. The SVF solution from patient GB1 (Gastric bypass 1) was 
isolated using the established method and found to contain 0.82 million WBC/ml whereas the Ma Sup contained 
0.33 million WBC/ml. One gram of WAT from patient GB2 contained 1.65 million WBC/ml in the SVF solution 
and 0.53 million WBC/ml. Patient GB3 had 1.72 million WBC/ml in the SVF solution and 1.53 million WBC/ml 
in the Ma Sup. The SVF solution from patient GB4 contained 0.63 million WBC/ml and the Ma Sup contained 
0.53 million WBC/ml, while the SVF solution of patient GB5 had 0.87 million WBC/ml and 0.47 million 
WBC/ml in the Ma Sup. The cell suspension volume for each SVF sample were 0.9 ml, and 0.6 ml for the Ma 
Sup 
Tissue 
ID
Type
Million 
cells/ml
Tot cell 
suspension 
volume (ml)
Million cells in cell 
suspension  volume 
(0.9 ml)
GB 3 SVF 1,8 x 106 0,9 1,62 x 106
Ma sup 1,46 x 106 0,6 0,88 x 106
GB 4 SVF 0,87 x 106 0,9 0,78 x 106
Ma sup Discharded
GB 5 SVF 0,8 x 106 0,9 0,72 x 106
Ma sup Discharded  
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Figure 5.16. Infiltrating cells in adipose tissue of patients from OUHA. WBCs in the SVF solution and in the 
matrix supernatant (Ma Sup) detected in patients GB1-GB5. 
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Adipose tissue was received from 5 patients undergoing gastric bypass at OUHA. For patient 
GB1 and GB2, the experiment was terminated after cell counting; whereas flow cytometry 
was conducted after cell counting for patients GB3-GB5.   
Finally, cell counting does not reveal the identity of the infiltrating cell. We wanted to 
determine the number and identity of immune cell related infiltrating cells, therefore we 
performed flow cytometry and IHC with antibodies to various immune cells. We also 
determined the form of infiltration by staining tissue samples with HE. 
5.4 Identification of infiltrating cells by flow 
cytometry (4 in figure 5.2) 
5.4.1 PBL from Ullevål University Hospital Oslo (a in figure 5.2) 
In order to perform flow cytometry on isolated cells from patient material the method was 
optimized on PBL from healthy donors at Ullevål University Hospital Oslo. PBLs were 
analyzed using anti-CD4, 8, 14, 19 and 56 conjugated to FITC. For optimal result we found 
that 0.5-1.0 x 10
6 
cells per well were optimal and 5 µl of each antibody.  
5.4.2 Flow cytometry for tissue from the gastric bypass patients 
from OUHA (b in figure 5.2) 
The SV cells for tissue GB3, GB4 and GB5 were analyzed by flow cytometry. 
Flow cytometry of the SVF cells from patient GB3 
For GB3, which contained the most cells the antibodies to the CD4, CD8, CD14, CD19 and 
CD56 markers were used. It was observed a 12% non-specific binding for the negative 
control (irrelevant antibody) (Figure 5.17). 
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Negative control (Mouse IgG1) for patient GB3 
 
Figure 5.17. SV cells of patient GB3 stained with irrelevant antibody. The right diagram demonstrates the 
fluorescence at the given wavelength of the fluorochrome FITC and the corresponding cell count. It shows 12% 
non-specific binding in the negative control. Forward (FSC-H) and side scatter (SSC-H) denotes size and the 
granularity of the cells. 
Moreover, 16% of the cells were positive for CD4, whereas 14.4% were positive for CD8 
and, 14.8% of the cells were CD14. Furthermore, 12.4% were positive for CD19 whereas 
14.6% were positive for CD56 (Figure 5.18 A-E). 
 
Figure 5.18. SV cells of patient GB3 stained with antibody to CD4 (A), CD8 (B) CD14 (C), CD19 (D) and 
CD56 (E).  It is observed that 16% of the cells are CD4 positive, 14.4% are positive for CD8, 14.8% are positive 
for CD14, 12.4% are positive for CD19 and 14.6 % positive for CD56. 
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Ma Sup for patient GB3, negative control (Mouse IgG1) 
As expected we monitored few cells (1.46 mill/mL) of the Ma Sup fraction of GB3. In fact we 
observed a great amount of non-specific binding and the peak profile was not comparable to 
the SV cells, although same cells were assumed to be present. No positive cells for the 
selection of antibodies were detected. Based on this result, flow was not conducted on the Ma 
Sup for the other patients (GB4 and GB5). 
 
Figure 5.19. Ma Sup cells of patient GB3 stained with irrelevant antibody. Diagram showing the negative 
control with non-specific binding and the altered peak profile. 
Flow cytometry of the SV cells from patient GB4 and GB5 
As mentioned above, very few cells were isolated from patient GB4 (0.77 x 10
6 
cells total) 
and GB5 (0.7 x 10
6 
cells total). In the case of GB4, only the antibody to the CD4 marker was 
used, and for GB5 the antibodies to the CD4 and CD19 markers were used. For GB4 the 
negative control showed 6% non-specific binding, whereas the GB5 revealed 6.5% non-
specific binding. 
Negative control (Mouse IgG1) for patient GB4 and GB5 
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Figure 5.20. SV cells of patient GB4 and GB5 stained with irrelevant antibody. (A) Cell population 
according to size and granularity for patient GB4. (C) Cell population according to size and granularity for 
patient GB5. (B) Cell population positive for irrelevant antibody. GB4 6% non-specific binding (B) and GB5 
6.5% non-specific binding (D). 
The CD4 antibody used for the SV cells of patient GB4 and GB5 
For patient GB4, 5.8% and for patient GB5, 7.2%, of the cells were positive for CD4 (Figure 
5.21, A and B below). 
 
Figure 5.21. SV cells of patient GB4 (A) and GB5 (B) stained with antibody to CD4. 5.8% of the cells from 
patient GB4 were CD4 positive. 7.2% of the cells from patient GB5 were positive for CD4.  
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The CD19 antibody used for the SV cells of patient GB5 
For GB5, 7.9% of the cells were positive for CD19 (Figure 5.22). 
 
Figure 5.22. SV cells of patient GB5 stained with antibody to CD19. 7.9% of the cells from patient GB5 were 
positive for CD19. 
5.5 Histology (1B in figure 5.2) 
Fat biopsies (subcutaneous and omental fat) were received from HUH and were donated by 
obese patients undergoing bariatric surgery. The biopsies were investigated pre and post 
surgery by microscopy after HE staining and IHC. These biopsies were compared to fat 
biopsies (subcutaneous fat) isolated from healthy controls. Biopsies showing infiltration 
outside blood vessel walls and in between the fat cells were selected for IHC. The control 
biopsies were also prepared for IHC in order to compare. To be able to detect a possible 
infiltrate, the biopsies were sectioned deeper. Pathologist and physician Professor Helge Scott 
accompanied the observations and the decision making. 
Fat biopsies of the obese patients included were a selection of the obese patients from the 
Dankel et al. study at UiB, as well as patients GB1- GB5 from the gastric bypass surgeries at 
OUHA. The biopsies from the controls were also from the Dankel et al. study. 
The histological observations of the obese patients and the controls included in this part of the 
project are summarized in the figures below. 
5.5.1 Control material 
Tissue slides of subcutaneous adipose tissue biopsies from the controls 4A2, 20A2 and 27A2 
were initially examined by light microscopy after HE staining. As can be observed, intact 
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appearing fat cells are observed (Figure 5.23A-C, arrows 1 and 2). No infiltrating cells, 
which should appear as smaller round cell of approximately size of 5-10 µm (Shido, 
Kobayashi et al. 1984; Krombach, Munzing et al. 1997), were observed. When performing 
IHC using anti-CD3, -CD20 and -CD68 we observed no positive staining for the selected 
antibodies concluding that there were no infiltrates of immune cells in the observed 
subcutaneous adipose tissue of the controls. 
 
Figure 5.23. HE stained subcutaneous adipose tissue biopsies of control. Intact fat cells and none infiltrating 
cells are observed. Original magnification x 200.  
5.5.2 Biopsies of obese patients  
Next we examined biopsies from the obese patients. Included in the figures below are the 
patient biopsies that displayed infiltrating cells when stained with HE. All the adipose tissue 
biopsies included from the obese patients were from the subcutaneous adipose tissue; this due 
to complete absence of infiltrates in the omental adipose tissue biopsies and due to 
subcutaneous adipose tissue being the only tissue obtained for the controls. 
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Patient 4A1 
The biopsies obtained for patient 4A1 are given below in order to show the difference in the 
tissue before and after the surgery, magnified x 40 (Figure 5.24 and 5.25) and x 200 (Figure 
5.26). For the pre surgery biopsy for patient 4A1 there was not detected any infiltration. 
 
Figure 5.24. HE stained pre surgery adipose tissue of patient, 4A1. Note fat cells and connective tissues 
indicated by arrows, showing fat cells and connective tissue in the obese patient. Original magnification x 40.  
However, when analyzing the post surgery biopsy we observed a modest infiltration of 
smaller cells that may represent immune cells (Figure 5.25 and 5.26). 
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Figure 5.25. Post surgery adipose tissue biopsy stained with HE from patient, 4A1. Note infiltrating cells 
(red circle) and connective tissue marked by arrows. Original magnification x 40. 
 
Figure 5.26. Left diagram displaying pre surgery adipose tissue biopsy from patient 4A1, stained with HE 
showing intact fat cells. Right diagram is post surgery showing infiltrating cells in the tissue. Original 
magnification x 200. 
Based on this, IHC was performed for this biopsy in order to determine the identity of these 
cells (Fig 5.27). This demonstrated that the biopsy was positive for cells expressing the CD3 
and CD68, but not for CD20 markers, respectively. Based on the antibodies used, these results 
suggested that there were some T cells (CD3+), and macrophages/monocytes present in the 
population of the infiltrating cells, however no B cells (CD20) were present.  
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Figure 5.27. HE and IHC staining of post surgery subcutaneous adipose tissue of patient 4A1.  Left panel:  
infiltrated post surgery adipose tissue stained with HE. Right three panels: IHC staining with anti-CD3 upper 
panel, anti-CD20 middle panel and anti-CD68, lower panel. Positive infiltrating cells are indicated by red circles 
for CD3 and CD68 whereas CD20 negative. The antibody specific infiltrating cells appears brown. Original 
magnification x 200. 
Patient 28 A1 
The biopsies obtained for patient 28A1 are given below in order to show the difference in the 
tissue before and after the surgery, magnified x 40 (Figure 5.28 and 5.29) and x 200 (Figure 
5.30). For the pre surgery biopsy no infiltration was detected (Fig 5.28). However, infiltration 
was observed for the post surgery biopsy (Figure 5.29). 
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Figure 5.28. Pre surgery adipose tissue biopsy with HE stain from patient, 28A1. Note fat cells indicated by 
arrows, showing fat cells in the obese patient. Original magnification x 40. 
 
Figure 5.29. Post surgery adipose tissue biopsy stained with HE from patient, 28A1. Note infiltrating cells 
(red circles) and connective tissue marked by arrows. Original magnification x 40. 
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Figure 5.30. Left diagram displaying pre surgery adipose tissue biopsy from patient 28A1, stained with HE 
showing intact fat cells. Right diagram is post surgery showing infiltrating cells. Original magnification x 200.  
Based on this finding, the biopsy was prepared for IHC to determine immune cells’ identity. 
This identified infiltrating cells positive for only anti-CD3, whereas cells positive for anti- 
CD20 and anti-CD68 were not detected, suggesting that the filtrate mainly consisted of T 
cells. 
 
Figure 5.31. HE and IHC staining of post surgery subcutaneous adipose tissue of patient 28A1. Left 
diagram displaying an overview of the infiltrate in the post surgery adipose tissue biopsy stained with HE from 
patient 28A1. IHC diagrams to the right, showing the CD3 positive infiltrating cells (red circle) on top. None of 
the cells were positive for CD 20 (middle) or for CD68 (bottom). The antibody specific infiltrating cells appears 
brown. Original magnification x 200. 
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Patient 10 A1 
When observing the HE stained biopsies obtained from patient 10A1 small infiltrates were 
detected in both pre and post surgery biopsies (Figure 5.32). 
 
Figure 5.32. Pre- and post surgery adipose tissue biopsy from patient 10A1, stained with HE. Left panel: 
shows blood vessel wall and infiltrating cells, indicated by arrows. Right panel: shows blood vessel wall and 
infiltrating cells in the tissue indicated by arrows. Original magnification x 200.  
In order to determine the cell identities by IHC, none of the cells present in the tissue were 
positive for the selected antibodies to the CD3, CD20 or CD68 markers (results not shown). 
Patient 27 A1 
When observing the HE stained biopsies obtained from patient 27A1 small amounts of 
infiltrating cells were detected in both pre and post surgery biopsies (Figure 5.33). The cells 
detected in the pre surgery biopsy were not considered an infiltrate, as the infiltrating cells 
appeared in the lumen of the blood vessel. However the cells in the post surgery biopsy were 
engaged in a minor infiltrate outside a blood vessel. 
 
65 
 
 
 
 
Figure 5.33. Pre- and post surgery adipose tissue biopsy from patient 27A1 stained with HE. Left diagram 
displaying pre surgery adipose tissue biopsy showing blood vessel wall and infiltrating cells in vessel lumen, 
indicated by arrows. Right diagram is post surgery showing blood vessel wall and infiltrating cells in the tissue 
indicated by arrows. Original magnification x 200. 
When conducting IHC none of the cells present in the tissue were positive for the selected 
antibodies to the CD3, CD20 or CD68 markers (results not shown). Original magnification x 
200.  
Patient 30A1 
When observing the HE stained biopsies obtained from patient 30A1 no infiltrates, only intact 
fat cells, were detected in the pre surgery biopsy, while a small infiltrate was observed in the 
post surgery biopsy. The post surgery biopsy showed destroyed fat cells (right diagram 
below). 
 
Figure 5.34. Pre and post surgery adipose tissue biopsy from patient 30A1. Left diagram displaying pre 
surgery adipose tissue biopsy from patient 30A1, stained with HE showing intact fat cells, indicated by arrows. 
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Right diagram is post surgery showing the small infiltrate, as well as destroyed fat cells, indicated by arrows. 
Original magnification x 200. 
When conducting IHC none of the cells present in the tissue were positive for the selected 
antibodies to the CD3, CD20 or CD68 markers (results not shown).  
Evaluation of the obese patients from HUH 
Of the obese patients included in the study, 5 of the 11 patients revealed infiltrating cells and 
the infiltrates were only seen in the post surgery subcutaneous adipose tissue biopsies. 
Based on the magnification used (x 200) it appears that the fat cells in the biopsies from the 
control persons in general were smaller than the fat cells from the obese patients. 
5.5.3 Biopsies from obese patients from OUHA  
All biopsies (omental and subcutaneous) obtained from the gastric bypass patients (GB1-
GB5) were pre surgery and all were stained by HE and with the complete absence of 
infiltrates. The pictures below show the subcutaneous pre surgery biopsy of patient GB1 and 
GB2, and the omental and subcutaneous pre surgery biopsy of patient GB3, GB4 and GB5. 
The omental biopsy was included since the fractionation method was performed on the same 
tissue; these biopsies were also negative for infiltration. 
IHC were performed on biopsy from patient GB1 and GB2, as expected due to the absence of 
infiltration, the results for all the antibodies were negative and results are not shown. 
HE stained biopsy section of patient GB1 and GB2 
When observing the HE stained biopsies from patient GB1 and GB2, it was only found intact 
fat cells and no infiltrating cells. 
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Figure 5.35. Both diagram displaying pre surgery subcutaneous adipose tissue biopsies (left: GB1, right: 
GB2). Biopsies stained with HE showing intact fat cells, indicated by arrows. Original magnification x 200.  
HE stained biopsy section of patient GB3, GB4 and GB5 
When observing the HE stained biopsies from patient GB3, GB4 and GB5, it was found intact 
fat cells in all patients, and a few infiltrating cells in the vessel walls (two of these shown 
below, indicated by arrows) in patient GB4. IHC was not performed on these tissues due to 
the observed absence of infiltrates. 
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Subcutaneous adipose tissue biopsy 
 
Figure 5.36. All diagrams displaying pre surgery subcutaneous adipose tissue biopsies (left: GB3, right: 
GB4 and bottom: GB5). Biopsies stained with HE showing intact fat cells, indicated by arrows. GB4 showing 
some infiltrating cells in two vessel walls. Original magnification x 200. 
 
Omental adipose tissue biopsy 
These slides were included since fractionation was performed on adipose tissue from same 
site. 
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Figure 5.37. All diagrams displaying pre surgery omental adipose tissue biopsies (left: GB3, right: GB4 
and bottom: GB5). Biopsies stained with HE showing intact fat cells, indicated by arrows. Original 
magnification x 200.  
Evaluation of the obese patients from OUHA 
Adipose tissue biopsies pre surgery was obtained, both subcutaneous and omental. Neither of 
the biopsies showed any infiltrates or accumulation of infiltrating cells. 
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6 Discussion 
6.1 Patient inclusion of obese patients from HUH 
and OUHA 
6.1.1 Numbers for female/male ratio for bariatric surgery 
For the adipose tissue biopsy part of the project, biopsies from 11 obese patients were 
received from HUH. These patients were eligible for biliopancreatic diversion with duodenal 
switch surgery. Out of these 11 obese patients, 77.7% were female, and 22.3% of them were 
male.  
When including obese patients at OUHA for the Intrafat pilot study, adipose tissue from 5 
patients was collected. Out of these five, four of these patients were females (80%) and one 
was male (20%).  
Relating these percentages to the literature in regards to the abundance of females undergoing 
bariatric surgery compared to men, it seems that the patient selection from HUH and OUHA 
based on sex, comply with several findings. Evidence shows that the majority of patients 
undergoing bariatric surgery are women, contributing to about 80% of all surgeries [39, 57-
59]. 
6.1.2 Blood samples obtained from the obese patients and controls 
at inclusion 
Blood samples from all the patients included at HUH obese (N=11) and the controls (N=3), 
were obtained. 
Unfortunately similar comprehensive blood tests (Intrafat blood analysis) were only obtained 
from 2 out of the 5 included patients at OUHA. This was due to time restrictions for the staff 
taking the blood tests for the other 3 patients. The regular blood test was obtained for the 3 
remaining patients and results were therefore incomplete in terms of metabolic parameters 
such as lipids, glucose and insulin values. 
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Interestingly for some of the patients, glucose levels were normal and the insulin levels were 
higher, this may indicate insulin resistance. For the obese patients included at OUHA, the 
blood glucose levels were similar to the obese patients at HUH, as they were considered 
normal, however one of the two patients who had the specific Intrafat blood analysis done 
showed dramatically increased insulin level, 85.4 mU/L (ref: <11 mU/L), being same 
observation seen in the obese patients from HUH. Furthermore, value that was increased for 
the same patient was Insulin C-peptide, this was 4906 pmol/L (ref: 370-1470 pmol/L). C-
peptide is a better indication of pancreatic insulin secretion than the level of insulin itself, 
reflecting that the β-cells are producing insulin [60]. Despite that these are only speculations 
based on the fact that many of the obese patients may have been on glucose lowering drugs, 
e.g. metformin [61]. However, as clinical information was restricted we can only speculate on 
this. 
For the lipid profile, the level of the total cholesterol was elevated for 5 of the 11 obese 
patients included at HUH, and for 2 of the 3 control persons. For all the obese patients the 
LDL cholesterol was greatly elevated, a feature that is observed in overweight and obese 
people, and a strong contributor to the development of atherosclerosis [62, 63]. 
The lipid values for the patients included at OUHA showed normal values, except from 
elevated TG values, this also being a contributor to atherosclerosis as explained above.  
The CRP values for the obese patients from HUH were significantly higher than for the 
controls (P= 0.004). It is recognized that overweight and obesity contribute to a low grade 
inflammation, which develops as fat mass increases [13, 64, 65]. Other pro-inflammatory 
factors in addition to CRP are also found to be elevated in obesity; these include TNF- α and 
IL-6 [24, 25, 64, 66]. The CRP values for the patients from OUHA were within the normal 
range. 
Based on the knowledge about elevated CRP values in terms of inflammation and that studies 
have found CRP and other inflammatory factors to be elevated in obese subjects, the 
motivation for developing a method in which could investigate infiltrates of immune cells and 
the detection of other inflammatory markers in obese patients was established. 
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6.2 Discussion of methods 
The consensus from recent research has shown that there is an increase in immune cells that 
correlates with weight gain and that obese people have a plasma and serum profile similar to 
those suffering from chronic diseases (Bruun et al. (2005), Lionetti et al. (2008), Curat et al. 
(2004), Weisberg et al. (2003)). These infiltrating cells, monocytes, macrophages, T- and B- 
cells have been found in the adipose tissue; in blood vessel walls, lumen of blood vessels and 
in between the adipocytes. Based on these findings, a fractionation method was established in 
order to isolate infiltrating cells in adipose tissue biopsies from obese patients and identifying 
these cells by flow cytometry. Adipose tissue was also investigated by the use of histology 
methods, HE staining and immunohistochemistry. 
6.2.1 Development of the fractionation protocol  
In order to determine the identity of the various cell infiltrates of WAT, we addressed this by 
fractionation. In order to do so we made changes for the optimization of a gravimetric 
fractionation protocol initially developed by others [55, 56]. 
Receiving adipose tissue biopsies 
When the adipose tissue biopsies were immersed HBSS 5% BSA, the medium was 
recommended to be at RT, or close to body temperature. Cold medium create extra stress for 
the body temperate adipose tissue once immersed.  
Medium 
Phosphate PBS was initially the medium of choice, but was changed to HBSS. HBSS contains 
glucose, which imitates a more physiological environment and will reduce any additional 
cellular stress, as well as containing a pH indicator.  
In addition to HBSS, M199 and FBS as also suggested as washing media, however this idea 
was rejected as HBSS was considered sufficient for washing and for incubation based on 
previous experiments on immune cells isolated from human blood [67]. 
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BSA 
The BSA had to be protease-, lipid- and immunoglobulin free in order to maintain optimal 
conditions of the adipose tissue and to prevent any further post operative triggering of 
inflammatory cells. Primarily, the BSA concentration for PBS was 0.1%. However based on 
previous experiments in the lab on immune cells this was modified to 5% in HBSS (Skålhegg 
personal conversation). The BSA product chosen only contained small amounts of fatty acids 
(0.01%) and endotoxins (0.3 Eu/mg) and was free of proteases and IgG (none detected).  
Enzyme 
Initially, it was suggested to dilute the collagenase enzyme in 6 ml PBS 0.1% BSA. The 
enzyme was added to pure HBSS, as it was experienced that the BSA interfered with the 
enzyme activity (Dankel personal conversation).   
The enzyme used initially was collagenase LB3, an enzyme blend that contained thermolysin. 
This was later changed to an enzyme mixture that contained dispase, collagenase Liberase 1, 
which was thought to be more favorable for the tissue. We decided to use LBTM Research 
Grade (previously called Collagenase LB3), as it turned out that the Collagen Liberase 1 was 
out of production. The new LBTM contains the same amount of thermolysin as LB3. 
Sample weight of the adipose tissue biopsy 
The weight of the adipose tissue biopsy was larger than the weight required for the 
fractionation protocol; therefore while optimizing the protocol, the additional adipose tissue 
was stored in the refrigerator overnight to repeat the protocol for practice purposes. The 
weight of tissue used for the fractionation protocol was decided to be approximately 1.0 gram 
per sample. Parallels were prepared for each adipose tissue biopsy obtained.  
The initial weight of the samples was between 0.7-0.8 grams. The sample weight was for 
some time adjusted to be between 2-3 grams by Simon Dankel as they achieved great cell 
counts with this weight. This increased tissue weight resulted in a greater amount of HBSS 
used, with15 ml of HBSS being mixed with 0.5 ml of the enzyme. 
This became one of the reasons as to why the final amount of tissue used ended up being 1 
gram. Using large amounts of tissue not only required larger amount of buffer, but was also 
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more time demanding. The final weight of adipose tissue to use for the final protocol was 
decided to be as close to 1 gram as possible. 
Incubation equipment 
In addition to the change in tissue weight and amount of HBSS, so was the incubation 
equipment and time. It was suggested to use a roller-mixer, which due to the amplified mixing 
movements created greater conditions for the enzyme and the chance of the complete 
digestion of the matrix fraction. It was experienced that the tissue did not reach a complete 
digestion when using the roller in RT. Hence, after the roller incubation, the tubes were 
transferred to the usual incubator cabinet which was set for 37 °C. This enhanced the 
digestion; however it lengthened the incubation time up to 2 hours. A further suggestion was 
to put the roller mixer in a incubator cabinet set for 37 °C, this could not be accommodated in 
Oslo, therefore the idea with the roller mixer was abandoned and the initial incubator cabinet 
was used again. From this experience it seemed that the enzyme had a better effect when 
incubated at 37 °C and it seemed that an incubation time of one hour was sufficient for the 
tissue to be digested, as long as the tissue was well cut up.  
Centrifugation 
The strength of the centrifugation when centrifuging the SVF solution was conferred. In the 
initial protocol it was suggested to, in the washing steps, centrifuge at a force of 1500 x g for 
10 minutes. The speed was used for blood analysis and was reduced as it was concluded that 
this force was to powerful for the SV cells and lead to disrupted cells (Dankel personal 
conversation). Hence, it was concluded that 585 x g for 5 minutes was the most appropriate 
force and time, and this was kept as speed all through the fractionation protocol. 
Matrix 
The literature mentions the remains of connective tissue, the matrix, post the collagenase 
digestion and how this fraction contains amounts of SV cells [26, 68]. It was initially 
suggested to incubate the undigested matrix together with the filter in the sieved SVF solution 
once the fat had been removed, and further treat the matrix and the SVF as one.  Because the 
matrix did not completely dissolve, the matrix was not further treated other than mixed with 
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the HBSS 5% BSA in a separate tube to release the SV cells embedded in the tissue, the 
supernatant was then counted for WBCs. 
6.2.2 The isolation and identification of non-fat cells from adipose 
tissue 
Cell lysis 
The original amount of ACT buffer being 1 ml in the initial protocol was considered too much 
based on the low number of cells. The 200 µl amount was used when the adipose tissue 
sample was 0.7-0.8 grams and increased according to the tissue weight. When the samples 
were between 2-3 grams the amount of lysis buffer was about 580 µl. When the weight of the 
adipose tissue was finalized to be 1.0 gram, it resulted in the amount of cell lysis buffer to be 
250 µl.  
As for the HBSS 5% BSA volume, it was changed to 800 µl when the adipose tissue sample 
was 0.7-0.8 grams. When testing with the larger tissue sample, this amount was increased in 
order to maintain the same conditions between the buffer and the medium. The eppendorph 
tubes used could fit 1.5 ml, therefore the SVF solution was further divided into two 
eppendorph tubes in order to accommodate for the required quantity. The decision of having 
the HBSS 5% BSA amount to be 800 µl was quite random, but seemed to work in relation to 
the amount of the lysis buffer. The eppendorph tube could fit this amount and one tube was 
used for the progression of the protocol. 
Cell counting 
It is known that the total WBC count, as well as the count of TNF-α, IL-6 and hsCRP, in 
blood tests are indicators of the metabolic syndrome and other inflammatory conditions in 
obese adults [69, 70]. In this thesis the WBCs were counted in the SVF of the adipose tissue 
obtained, the normal proportion of the WBCs in the SVF of adipose tissue is unknown. 
However the proportions of the identified immune cells can reveal information about the 
condition of the patient. 
When optimizing the fractionation method, the adipose tissue obtained from the Pathology 
Department at Rikshospitalet HF was from deceased patients. The prerequisites given were to 
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minimize the time between death and autopsy, tissue showing no sign of autolysis and that the 
adipose tissue was taken from the mesentery, the membrane that attaches the intestines to the 
abdominal wall. This location is close to where the adipose tissue was collected from the 
gastric bypass patients. Suggestions of variables that might have affected the adipose tissue 
upon collection were time delay between death and autopsy, temperature variations, if the 
deceased had a fever at time of death, if the deceased was recently operated in the abdomen 
and general cause of death. 
The WBC count obtained from the adipose tissue biopsies from the Pathology Department 
could have been affected by many variables, such as the time of death of the patients, 
unknown clinical information about the patients, and storing time of the adipose tissue. With 
the main issue being that the adipose tissue was from deceased patients, the WBC count was 
not compared to the WBC count from the adipose tissue obtained from the obese patients at 
OUHA. Since not comparable, the adipose tissue biopsies received from the Pathology 
Department were rather recognized as indispensable material during the optimization of the 
fractionation protocol before the adipose tissue from the obese gastric bypass patients from 
OUHA were obtained. 
Flow cytometry  
The selected antibodies were against the CD4, CD8, CD14, CD19 and CD56 markers and 
were all conjugated to the fluorochrome FITC. These were introduced when optimizing the 
flow cytometry protocol on PBL. Flow cytometry was not performed on the tissue from the 
Pathology Department at Rikshospitalet HF, but on the SV cells from patient GB3, GB4 and 
GB5. The antibodies against these markers were chosen due to the broad range of cell 
identification they provide in a heterogenic cell suspension such as PBL and SV cells.  
It was recommended to have between 0.5- 1.0 million WBCs per well, and preferably 12 
wells were going to be used (parallels of the 6 antibodies), if sufficient amount of cells. When 
optimizing the flow cytometry method using PBL there average cell concentration was 7.5 
million cells/ml, which was sufficient amount of cells as the total cell suspension volume was 
5 ml. This volume made it possible to up concentrate the cells. However, when applying the 
flow cytometry method on the SV cells from patients GB3, GB4 and GB5, the average cell 
concentration was 1.2 million cells/ml, and the total cell suspension volume was 0.9 ml in 
which made it, due to the low cell count, impossible to up concentrate so that sufficient cell 
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number for the 12 wells was obtained. In result, the cells from patient GB3 were up 
concentrated as allowed by the volume in order to supply 6 wells (negative control, CD4, 
CD8, CD14, CD19 and CD56) with cells, although aware that cell volume was insufficient. 
This was mainly done for practice purposes. For patient GB4, the WBC count only allowed 2 
antibodies to be tested (negative control and the antibody for CD4). The CD4 was selected 
based on suggestions from the literature that T-cells precedes the infiltration of macrophages 
and initiate macrophage recruitment in mice [71] and that CD4+ cells possibly diminish in 
high-fat diet fed mice [16]. CD4 also showed more positive cells when conducting flow on 
the PBL, compared to CD8. For patient GB5, the cell count allowed for negative control, CD4 
and CD19 to be tested, basically to compare to the results from patient GB3 and GB4. 
When performing flow cytometry on the Ma Sup, the results indicated that there were no 
infiltrating cells of immunological nature, seeing as the literature suggests that SV cells are 
embedded in the matrix, it might of interest to develop a method in which is suited for this 
cell suspension [26].  The Ma Sup for patient GB4 and GB5 did not undergo flow cytometry 
based on the experiences from patient GB3.  
The flow software Cell Quest was taught during optimization and the settings saved from the 
PBL trials were applied for the SV cells from the adipose tissue. The settings were slightly 
changed; similar peaks were obtained between the two tissue types, but the scatter plot 
displayed a dissimilar pattern, indicating the cell population of the SV cells is different to the 
PBL. Due to limited cell number and the total cell suspension, titration of the antibodies were 
not conducted, therefore the most suited antibody concentration for the SV cells from adipose 
tissue was unknown.  
Table 6.1. Identified lymphocytes and macrophages in the SV cells from the obese patients from OUHA. 
  GB3 GB4 GB5 
CD4 16 % 5.8 % 7.2 % 
CD8 14.1 %     
CD14 14.8 %     
CD19 12.4 %   7.9 % 
CD56 14.6 %     
 
 A complete range of the selected antibodies were applied to the SV cells of patient GB3, 
whereas the low SV cell count resulted in incomplete antibody identification for patient GB4 
and GB5. 
78 
 
 
 
Suggested immune cell distribution in WBCs from blood: Granulocytes: 40-60%, 
Lymphocytes: 20-40% and Macrophages: 2-8% [72]. If lymphocytes are elevated it indicates 
chronic inflammation ([73]  and Helge Scott personal conversation). The total percentage of 
lymphocytes from patient GB3 from the SV cells was 57%.  
Cell counting and flow cytometry for GB1-GB5 
The obese patients from OUHA had an average BMI of 49.7 kg/m
2
 (classified morbidly 
obese). Based on the evidence that as fat mass increases so does the adipokines and the 
chemokines in the blood stream, and hence the inflammatory factors, such as macrophages 
and leukocytes, it was assumed that the WBC count would be elevated in the SVF solution 
from these patients [20, 23, 27, 74]. The average number of WBCs obtained from the cell 
counts was 1.2 million cells / ml, however, the WBC count results could only be compared to 
other obese patients and to lean healthy controls in order to elucidate whether the obese 
patients’ WBC count was elevated.  
The optimization of flow cytometry was conducted on PBL from apparently healthy donors 
before flow cytometry was performed on SVF solution from adipose tissue collected from 
obese patients. The detected WBCs in the SVF solution were from adipose tissue, where the 
distribution of the various cells was unknown. It is therefore inappropriate for the WBCs from 
the SVF solution to be compared to the normal distribution range of the various cell types 
found in blood. The result from the flow cytometry for patient GB3 showed that 57% of the 
cells in the SVF solution were lymphocytes. This percentage could only be used to as a 
reference when flow cytometry was performed on SVF solution from other obese patients, as 
well as from healthy persons. Based on the established evidence from the literature that 
obesity contributes to a systemic low grade chronic inflammation, where the immune cells are 
increased, it can only be speculated if the obtained amount of lymphocytes from patient GB3 
was increased compared to lean subjects. 
The results from the cell counting and flow cytometry were not the main drive behind the 
experiment, but rather optimization and establishment of the methods for the continuation of 
the project. 
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6.3 Biopsy slides from the patients from HUH 
6.3.1 HE stained biopsies from the obese patients 
Upon the microscopic observations, it was experienced that only a few of the adipose tissue 
biopsies had infiltrates of immune cells, in which all of these were exclusively from the post 
surgery subcutaneous adipose tissue biopsies. In fact, none of the slides with infiltrating cells 
were from the pre- surgery subcutaneous or omental biopsies or post surgery omental adipose 
tissue biopsies. Due to the total size of the adipose tissue of the obese patients, infiltrations 
might have been unintentionally excluded due to the location of which the biopsy was taken 
from. The number of infiltrates per patient is unknown and therefore the negative adipose 
tissue biopsies might have infiltrates on other locations of the tissue. However, the adipose 
tissue biopsies were obtained from the approximately same place on each of the patients. The 
negative results might also be due to the immune infiltrates being further inside the biopsy. A 
serial of sections of all the biopsies were obtained in order to possibly detect infiltrating cells 
deeper in the biopsy, though this did not affect the results. 
Metabolic disorders, such as T2DM, dyslipidemia and HT, improves or resolves as a result of 
the dramatic weight loss experienced post bariatric surgery [38, 75-77]. This is thought to 
occur due to the reduction in fat mass, hence the decreased secretion of inflammatory factors 
such as TNF-α, IL-6, MCP-1, other cytokines and attracted monocytes and macrophages [32, 
74, 78, 79]. Reduction in macrophage number found in morbidly obese has also been reported 
post surgically induced weight loss [27]. Based on these results, it was not expected to find 
infiltrating cells in the post surgery biopsies, but rather in the pre surgery biopsies. 
Findings from the literature suggest that the visceral adipose tissue is more metabolically 
active than the subcutaneous in terms of the secretion of inflammatory factors (TNF-α, IL-1β, 
IL-6) by adipose tissue macrophages (ATM) and other cells in the SVF of the adipocytes [19, 
20]. Others have shown that there is a greater infiltration rate of monocytes in visceral tissue 
than in subcutaneous due to the increased release of MCP-1 from this fat depot which is 
important for the macrophage activation in adipose tissue [18, 75]. Adding on to these 
indications, Cancello et al. found twice as many macrophages in omental/visceral fat depot as 
in the subcutaneous fat depot from 55 obese subjects [64]. The biopsies studied in this project 
that showed infiltrating cells were solely from the subcutaneous adipose tissue, conflicting 
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with the results mentioned above. Little can be concluded from these observations, however 
based on this patient material, we suggest that there is some low degree of immune activity 
post surgery in the subcutaneous adipose tissue.  
A study, Cancello et al. showed images of adipocytes and macrophages pre bariatric surgery 
and post surgery in morbidly obese subjects [27]. The images of macrophages surrounding 
adipocytes in a CLS pre surgery were thought to be a typical artifact of low chronic 
inflammation, seeing as no such formations were observed after the surgery and weight loss. 
They as well as numerous of other studies have showed images of crown-like formation of 
macrophages surrounding adipocytes before weight loss surgery. These CLSs are thought to 
be macrophages surrounding adipocytes with features of necrosis, implying that the 
macrophages exhibit some phagocytic properties. When adipocytes reach a critical size, it 
supposedly triggers apoptosis, hence the macrophage infiltration. These CLSs have been 
reported in adipose tissue from both mice and humans [33, 80-82]. These CLSs are referred to 
as a general structure of macrophage infiltration observed in the adipose tissue pre surgery. 
What was surprising in this project was that no such structures or similar ones were detected 
when observing the biopsy sections through the microscope. Not even in the biopsies 
displaying infiltrates. The total absence of these macrophage formations seen in our sample 
might imply that these structures are not a significant sign of inflammation, but rather 
showing one of the functions of the macrophages infiltrating the adipose tissue. By 
investigating the diagrams of the studies that have detected these formations, the CLS are not 
abundant in the adipose tissue, but rather scattered around in the tissue. 
The post surgery subcutaneous biopsy for patient 28A1 showed the most infiltrating cells. It 
was different to the other infiltrates observed as there were large fat vacuoles (oil cysts), 
infiltrating cells and an increase in connective tissue. These observations suggested that the 
part of the adipose tissue in this patient was necrotic; where the fat vacuoles had engulfed the 
fat from the destroyed adipocytes, while the empty adipocytes created connective tissue. It 
was suggested that macrophages were involved in this process (Helge Scott personal 
conversation). This observation indicated that the adipose tissue is active post surgery; 
however this could have been brought by an external factor, such as a tight belt, a firm grip or 
a punch etc. 
As mentioned previously, no infiltrations were found in the biopsies from the control patients. 
The adipose tissue of lean and normal weight people have been estimated to contain about 
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10% macrophages, whereas obese humans are assumed to have 50% of macrophages in 
adipocytes [34]. Other biochemical data obtained from the controls were normal; hence the 
expectation of the complete absence of infiltrating cells in the adipose tissue. 
The obese patients which donated the adipose tissue biopsies had a significant weight loss (P= 
<0.005), as well as significant reduction in the CRP value (P= <0.001) post surgery, 
indicating, based on findings from the literature, that inflammation is reduced. It was, 
however, only observed infiltrating cells in the post surgery subcutaneous biopsies. This 
proposes the idea that other immune factors are involved in the course of the inflammatory 
process which has not been investigated in this thesis. 
6.3.2 Immunohistochemistry of biopsies from the patients 
When conducting IHC on the cells present in the infiltrates of the biopsy sections, the aim 
was to categorize the cells by using the antibodies for T- and B- cells, and for macrophages, 
CD3, CD20 and CD68 respectively. The antibodies selected were chosen as these immune 
cells have been detected in morbidly obese subjects in previous studies [22, 27, 83]. Due to 
the small amounts of cells present in the infiltrates detected, it was appropriate to not use an 
extensive range of antibodies in order to identify the infiltrating cells. The positive biopsies 
were sectioned onto super frost glass slides and prepared for IHC. The biopsies of the control 
patients were also prepared.  
When observing the stained sections, it was experienced that the infiltrations were shallow.  
Some of the infiltrates did not penetrate the 10 consecutive sections prepared for IHC making 
it impossible to investigate the three antibodies in the same infiltrate, seeing as section 1-3 
was for one antibody and so on. Based on the microscopic investigation of the slides, it 
seemed that more T- and B- cells were present in the infiltrates than CD68 presenting 
macrophages. Theories from recent research have questioned the possibility that there might 
be a T- and B-cell stimulation prior to the macrophage infiltration in adipose tissue [16, 31], 
something that might explain the apparent majority of the T- and B- lymphocytes. However, 
due to the overall small amount of infiltrating cells, the perceptible abundance of T- and B- 
cells was not necessarily a correct observation, and a result can only be drawn from this if 
more biopsies would have been positive for infiltration. In addition to this, the findings were 
conflicting with the other literature stating a reduction in inflammation post surgery [27, 84].  
82 
 
 
 
Although some of the HE stained biopsies were showing infiltrating cells, the markers used in 
the IHC (antibodies for CD3, CD20 and CD68) turned out not recognizing any of the cells 
present in the infiltrates for patient 10A1, 27A1 and 30A1, hence IHC did not aid 
identification of the infiltrating cells. Due to these outcomes, the results were not shown. 
It should be noted that there was no difference between the blood test of the patients in which 
showed an infiltrate after IHC was performed (Patients 4A1 and 28A1) compared to the other 
patients who did not show any infiltrating cells, the CRP was significantly reduced, as well as 
insulin and blood glucose level post surgery. What it is that initiates the infiltrations, or at 
least increase the infiltrating cells when the biochemical parameters obtained from blood tests 
are close to normalized one year after the surgery can be a range of variables.  
Given that the minority of the infiltrating cells were identified, it can be questioned what kind 
of cells are present in the infiltrates. Granulocytes were not investigated but can be suggested 
as present cells; however these cells are usually present early in inflammations and are the 
first cells to be at the site of damage [85, 86]. Based on this it has been discussed whether the 
possible presence of granulocytes are there due to a recent exterior impact, ex. wearing a tight 
belt or tight clothes, experienced a recent minor incident creating a punch, or a firm grip in the 
area where the biopsies are collected from post surgery (Helge Scott personal conversation). 
There were no infiltrating cells for the control patients, they appeared as the pre surgery 
adipose tissue biopsies; only smaller fat cell size was noted as difference. 
6.4 Biopsy slides from the patients from OUHA 
The biopsies were from pre surgery, and as experienced with the biopsies from HUH, the pre 
surgery biopsies were free of infiltrating cells. Although several sections were prepared no 
infiltrates were observed and no staining was positive when performing IHC. These findings 
support the other findings in the biopsies from HUH, indicating that there seem to be a slight 
up regulation of unidentified immune cells post surgery, rather than pre surgery, in which 
creates an inflammatory looking tissue. It will be interesting to observe biopsies from these 
patients post surgery (one year after surgery), in order to compare if the same is experienced 
for these patients as for the patients and the post surgery biopsies from HUH. 
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7 Conclusion 
Blood tests collected from the obese patients at HUH showed a significant decrease in CRP 
values post surgery, results that propose a reduction of inflammatory conditions after 
significant weight loss. 
A method for the fractionation of adipose tissue in order to isolate and to further identify 
immune cells was optimized in this present study. Enzymatic digestion enabled the separation 
of fat cells and the SVF, where the cells of interest are embedded. A fraction of these immune 
cells were identified by performing flow cytometry, with antibodies for T- and B- cells, 
macrophages and NK-cells. These cells are believed to be involved in the low grade chronic 
inflammation observed in obese subjects. 
From HUH, adipose tissue biopsies were obtained from 11 bariatric surgery patients before 
and after surgery and 3 control patients. Microscopic observations of HE stained sections, pre 
surgery adipose biopsies from morbidly obese patients revealed no infiltrates of immune cells. 
These results were further supported by pre surgery adipose tissue biopsies from 5 patients at 
OUHA where no infiltrates were found. No infiltrates were found in the control biopsies. 
Post surgery subcutaneous adipose tissue biopsies revealed infiltrates of immune cells, with 5 
of 11 patient biopsies being positive.  
Analysis by IHC concluded that 2 of 5 biopsies were infiltrated with immune cells as judged 
by the antibodies used.   
Modest conclusions can be drawn from these observations, as only 2 of the 11 patients 
displayed infiltrating cells in which was identified by IHC. However based on the findings 
that only post surgery biopsies showed infiltrates, although CRP significantly reduced, might 
suggest an underlying mechanisms in which low grade inflammation is present  post surgery. 
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